Charles River Laboratories International (CRL) 10-Q4 Aug 212021 Q2 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 26, 2021	Jul. 23, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 26, 2021
Document Transition Report	false
Entity File Number	001-15943
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	CRL
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,396,622
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-25
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Total revenue	$ 914,607	$ 682,584	$ 1,739,173	$ 1,389,643
Costs and expenses:
Selling, general and administrative	171,501	127,712	327,234	257,613
Amortization of intangible assets	32,970	27,758	61,812	55,637
Operating income	137,550	76,768	261,253	171,049
Other income (expense):
Interest income	171	276	206	592
Interest expense	(16,190)	(19,352)	(45,909)	(34,419)
Other income (expense), net	5,965	26,260	(21,752)	2,189
Income before income taxes	127,496	83,952	193,798	139,411
Provision for income taxes	37,580	16,284	39,947	20,906
Net income	89,916	67,668	153,851	118,505
Less: Net income attributable to noncontrolling interests	1,468	233	3,873	301
Net income attributable to common shareholders	$ 88,448	$ 67,435	$ 149,978	$ 118,204
Earnings per common share
Basic (in dollars per share)	$ 1.76	$ 1.36	$ 2.99	$ 2.39
Diluted (in dollars per share)	$ 1.72	$ 1.34	$ 2.93	$ 2.36
Weighted-average number of common shares outstanding:
Basic (in shares)	50,297	49,553	50,138	49,371
Diluted (in shares)	51,334	50,246	51,225	50,118
Service
Total revenue	$ 715,320	$ 550,561	$ 1,341,901	$ 1,097,153
Costs and expenses:
Cost of services provided and products sold (excluding amortization of intangible assets)	476,762	374,938	900,737	747,762
Product
Total revenue	199,287	132,023	397,272	292,490
Costs and expenses:
Cost of services provided and products sold (excluding amortization of intangible assets)	$ 95,824	$ 75,408	$ 188,137	$ 157,582

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 89,916	$ 67,668	$ 153,851	$ 118,505
Other comprehensive income (loss):
Foreign currency translation adjustment	20,827	6,750	30,656	(38,105)
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	993	1,365	1,981	2,739
Comprehensive income, before income taxes related to items of other comprehensive income	111,736	75,783	186,488	83,139
Less: Income tax expense (benefit) related to items of other comprehensive income	2,449	1,862	1,424	(177)
Comprehensive income, net of income taxes	109,287	73,921	185,064	83,316
Less: Comprehensive income (loss) related to noncontrolling interests, net of income taxes	1,843	284	4,233	(192)
Comprehensive income attributable to common shareholders, net of income taxes	$ 107,444	$ 73,637	$ 180,831	$ 83,508

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Current assets:
Cash and cash equivalents	$ 222,969	$ 228,424
Trade receivables and contract assets, net of allowances for doubtful accounts of $7,538 and $6,702, respectively	644,027	617,740
Inventories	194,341	185,695
Prepaid assets	84,610	96,712
Other current assets	121,966	72,560
Total current assets	1,267,913	1,201,131
Property, plant and equipment, net	1,189,120	1,124,358
Operating lease right-of-use assets, net	276,820	178,220
Goodwill	2,540,067	1,809,168
Client relationships and other intangible assets, net	1,056,775	787,599
Deferred tax assets	31,863	37,729
Other assets	357,794	352,626
Total assets	6,720,352	5,490,831
Current liabilities:
Current portion of long-term debt and finance leases	3,021	50,214
Accounts payable	110,926	122,475
Accrued compensation	223,063	206,823
Deferred revenue	231,329	207,942
Accrued liabilities	228,972	149,820
Other current liabilities	132,299	102,477
Total current liabilities	929,610	839,751
Long-term debt, net and finance leases	2,727,240	1,929,571
Operating lease right-of-use liabilities	239,484	155,595
Deferred tax liabilities	262,562	217,031
Other long-term liabilities	207,377	205,215
Total liabilities	4,366,273	3,347,163
Commitments and contingencies (Notes 2, 9, 11, 12, 16 and 17)
Redeemable noncontrolling interests	30,799	25,499
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 50,538 shares issued and 50,391 shares outstanding as of June 26, 2021, and 49,767 shares issued and outstanding as of December 26, 2020	505	498
Additional paid-in capital	1,690,861	1,627,564
Retained earnings	775,392	625,414
Treasury stock, at cost, 147 and 0 shares, as of June 26, 2021 and December 26, 2020, respectively	(40,297)	0
Accumulated other comprehensive loss	(108,021)	(138,874)
Total equity attributable to common shareholders	2,318,440	2,114,602
Noncontrolling interest	4,840	3,567
Total equity	2,323,280	2,118,169
Total liabilities, redeemable noncontrolling interests and equity	6,720,352	5,490,831
Client relationships, net
Current assets:
Client relationships and other intangible assets, net	964,324	721,505
Other intangible assets, net
Current assets:
Client relationships and other intangible assets, net	$ 92,451	$ 66,094

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 7,538	$ 6,702
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	50,538,000	49,767,000
Common stock, shares outstanding (in shares)	50,391,000	49,767,000
Treasury stock, shares (in shares)	147,000	0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Cash flows relating to operating activities
Net income	$ 153,851	$ 118,505
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	129,613	114,468
Stock-based compensation	30,266	24,103
Debt extinguishment and financing costs	27,980	0
Deferred income taxes	8,891	148
Loss (gain) on venture capital and strategic equity investments, net	6,910	(11,876)
Other, net	(475)	10,487
Changes in assets and liabilities:
Trade receivables and contract assets, net	(5,224)	(19,371)
Inventories	(7,107)	(1,901)
Accounts payable	(13,383)	(25,619)
Accrued compensation	13,932	8,728
Deferred revenue	502	(3,273)
Customer contract deposits	(2,032)	8,276
Other assets and liabilities, net	13,095	8,221
Net cash provided by operating activities	356,819	230,896
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(1,000,505)	(382,250)
Capital expenditures	(74,461)	(52,521)
Purchases of investments and contributions to venture capital investments	(23,266)	(12,064)
Proceeds from sale of investments	5,204	5,681
Other, net	839	(1,157)
Net cash used in investing activities	(1,092,189)	(442,311)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	4,999,942	1,411,953
Proceeds from exercises of stock options	35,298	36,608
Payments on long-term debt, revolving credit facility, and finance lease obligations	(4,241,772)	(1,045,235)
Purchase of treasury stock	(40,297)	(23,793)
Payment of debt extinguishment and financing costs	(38,166)	0
Other, net	(2,330)	(4,417)
Net cash provided by financing activities	712,675	375,116
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	17,066	295
Net change in cash, cash equivalents, and restricted cash	(5,629)	163,996
Cash, cash equivalents, and restricted cash, beginning of period	233,119	240,046
Cash, cash equivalents, and restricted cash, end of period	227,490	404,042
Supplemental cash flow information:
Cash and cash equivalents	222,969	402,020
Restricted cash included in Other current assets	3,118	465
Restricted cash included in Other assets	1,403	1,557
Cash, cash equivalents, and restricted cash, end of period	$ 227,490	$ 404,042

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Equity Attributable to Common Shareholders	Noncontrolling Interest
Beginning balance (in shares) at Dec. 28, 2019		48,936				0
Beginning balance at Dec. 28, 2019	$ 1,637,828	$ 489	$ 1,531,785	$ 280,329	$ (178,019)	$ 0	$ 1,634,584	$ 3,244
Increase (Decrease) in Stockholders' Equity
Net income	51,168			50,769			50,769	399
Other comprehensive income (loss)	(40,898)				(40,898)		(40,898)
Purchase of a 10% redeemable noncontrolling interest and recognition of related contingent consideration	(2,379)		(2,379)				(2,379)
Issuance of stock under employee compensation plans (in shares)		694
Issuance of stock under employee compensation plans	22,623	$ 7	22,616				22,623
Acquisition of treasury shares (in shares)						144
Acquisition of treasury shares	(23,675)					$ (23,675)	(23,675)
Stock-based compensation	10,960		10,960				10,960
Ending balance (in shares) at Mar. 28, 2020		49,630				144
Ending balance at Mar. 28, 2020	1,655,627	$ 496	1,562,982	331,098	(218,917)	$ (23,675)	1,651,984	3,643
Increase (Decrease) in Stockholders' Equity
Net income	67,876			67,435			67,435	441
Other comprehensive income (loss)	6,203				6,203		6,203
Issuance of stock under employee compensation plans (in shares)		174
Issuance of stock under employee compensation plans	13,994	$ 2	13,992				13,994
Acquisition of treasury shares (in shares)						1
Acquisition of treasury shares	(118)					$ 118	118
Stock-based compensation	13,143		13,143				13,143
Ending balance (in shares) at Jun. 27, 2020		49,804				145
Ending balance at Jun. 27, 2020	1,756,725	$ 498	1,590,117	398,533	(212,714)	$ (23,793)	1,752,641	4,084
Beginning balance (in shares) at Dec. 26, 2020		49,767				0
Beginning balance at Dec. 26, 2020	2,118,169	$ 498	1,627,564	625,414	(138,874)	$ 0	2,114,602	3,567
Increase (Decrease) in Stockholders' Equity
Net income	62,220			61,530			61,530	690
Other comprehensive income (loss)	11,857				11,857		11,857
Adjustment of redeemable noncontrolling interest to redemption value	(835)		(835)				(835)
Issuance of stock under employee compensation plans (in shares)		583
Issuance of stock under employee compensation plans	19,612	$ 6	19,606				19,612
Acquisition of treasury shares (in shares)						134
Acquisition of treasury shares	(36,028)					$ (36,028)	(36,028)
Stock-based compensation	13,189		13,189				13,189
Ending balance (in shares) at Mar. 27, 2021		50,350				134
Ending balance at Mar. 27, 2021	2,188,184	$ 504	1,659,524	686,944	(127,017)	$ (36,028)	2,183,927	4,257
Increase (Decrease) in Stockholders' Equity
Net income	89,031			88,448			88,448	583
Other comprehensive income (loss)	18,996				18,996		18,996
Adjustment of redeemable noncontrolling interest to redemption value	(1,506)		(1,506)				(1,506)
Issuance of stock under employee compensation plans (in shares)		188
Issuance of stock under employee compensation plans	15,767	$ 1	15,766				15,767
Acquisition of treasury shares (in shares)						13
Acquisition of treasury shares	(4,269)					$ (4,269)	(4,269)
Stock-based compensation	17,077		17,077				17,077
Ending balance (in shares) at Jun. 26, 2021		50,538				147
Ending balance at Jun. 26, 2021	$ 2,323,280	$ 505	$ 1,690,861	$ 775,392	$ (108,021)	$ (40,297)	$ 2,318,440	$ 4,840

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) (Parenthetical)	Feb. 29, 2020
Redeemable Noncontrolling Interest
Noncontrolling interest ownership percentage	10.00%

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Jun. 26, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2020. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The COVID-19 pandemic is dynamic, and its ultimate scope, duration and effects are uncertain. This pandemic has and continues to result in, and any future epidemic or pandemic crises may potentially result in, direct and indirect adverse effects on the Company’s industry and customers, which in turn has (with respect to COVID-19) and may (with respect to future epidemics or crises) impact the Company’s business, results of operations and financial condition. Further, the COVID-19 pandemic may also affect the Company’s operating and financial results in a manner that is not presently known to the Company or that the Company currently does not expect to present significant risks to its operations or financial results. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research Products businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services). Research Products supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics as well as contract development and manufacturing; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2020. Newly Adopted Accounting Pronouncements In January 2020, the Financial Accounting Standards Board (FASB) issue d ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. This standard became effective for the Company in the three months ended March 27, 2021 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities, the incremental approach for intraperiod tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This standard became effective for the Company in the three months ended March 27, 2021 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU, including subsequently issued updates, offers temporary optional expedients and exceptions for applying U.S. GAAP to modifications to agreements such as loans, debt securities, derivatives, and borrowings which reference LIBOR or another reference rate that will partially discontinue after December 31, 2021 and fully cease by June 30, 2023. The expedients and exceptions provided by the standard do not apply to modifications made and hedging relationships entered into or evaluated after that, except for hedging relationships existing as of the phase-out date that an entity has elected certain optional expedients for and are retained through the end of the hedging relationship. The ASU is effective until the replacement for LIBOR is completed. The interest rate on the Company’s revolving credit facility, which was amended and restated in April 2021 (see Note 9. Long-term debt and finance lease obligations) and matures in fiscal year 2026, is linked to LIBOR and alternative interest rates when LIBOR is discontinued. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption.

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS	6 Months Ended
BUSINESS COMBINATIONS	Jun. 26, 2021
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS Vigene Biosciences, Inc. On June 28, 2021 (third fiscal quarter of 2021), the Company acquired Vigene Biosciences, Inc. (Vigene), a gene therapy contract development and manufacturing organization (CDMO), providing viral vector-based gene delivery solutions. The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The preliminary purchase price of Vigene was $292.5 million in cash, subject to customary closing adjustments, with additional contingent payments of up to $57.5 million based on future performance. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business will be reported as part of the Company’s Manufacturing reportable segment. Due to the limited time between the acquisition date and the filling of this Quarterly Report on Form 10-Q, it is not practicable for the Company to disclose the preliminary allocation of the purchase price to assets acquired and liabilities assumed. The Company incurred transaction and integration costs in connection with the acquisition of $2.5 million for both the three and six months ended June 26, 2021 , which were included in Selling, general and administrative expenses within t he unaudited condensed consolidated statements of income. Retrogenix Limited On March 30, 2021 (second fiscal quarter of 2021), the Company acquired Retrogenix Limited (Retrogenix), an early-stage contract research organization providing specialized bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances the Company’s scientific expertise with additional large molecule and cell therapy discovery capabilities. The preliminary purchase price of Retrogenix was $53.1 million, net of $8.5 million in cash, subject to certain post-closing adjustments that may change the purchase price. Included in the preliminary purchase price are additional contingent payments fair valued at $6.9 million, which is the maximum potential payout, and is based on a probability-weighted approach. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. The preliminary purchase price allocation of $53.1 million, net of $8.5 million of cash acquired was as follows: March 30, 2021 (in thousands) Trade receivables $ 2,266 Other current assets (excluding cash) 209 Property, plant and equipment 400 Goodwill 33,625 Definite-lived intangible assets 22,126 Other long-term assets 1,385 Current liabilities (1,569) Deferred tax liabilities (4,174) Other long-term liabilities (1,205) Total purchase price allocation $ 53,063 The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 17,340 13 Developed technology 3,685 3 Other intangible assets 1,101 2 Total definite-lived intangible assets $ 22,126 11 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA business from new customers introduced to Retrogenix and the assembled workforce of the acquired business. The goodwill attributable to Retrogenix is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $0.9 million and $1.7 million for the three and six months ended June 26, 2021 , respectively, which were included in Selling, general and administrative expenses within t he unaudited condensed consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been included because Retrogenix’ s financial results are not significant when compared to the Company’s consolidated financial results. Cognate BioServices, Inc. On March 29, 2021 (second fiscal quarter of 2021), the Company acquired Cognate BioServices, Inc. (Cognate), a cell and gene therapy CDMO offering comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain. The acquisition of Cognate establishes the Company as a scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through cGMP production. The preliminary purchase price of Cognate was $876.1 million, net of $70.5 million in cash, subject to certain post-closing adjustments and includes $15.7 million of consideration for an approximate 2% ownership interest not acquired, which will be redeemed in 2022 with the ultimate payout tied to performance in 2021. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility and recently issued Senior Notes. This business is reported as part of the Company’s Manufacturing reportable segment. The preliminary purchase price allocation of $876.1 million, net of $70.5 million of cash acquired was as follows: March 29, 2021 (in thousands) Trade receivables $ 16,564 Inventories 4,231 Other current assets (excluding cash) 9,840 Property, plant and equipment 52,082 Operating lease right-of-use assets, net 34,349 Goodwill 603,379 Definite-lived intangible assets 266,700 Other long-term assets 6,098 Deferred revenue (18,582) Current liabilities (32,517) Operating lease right-of-use liabilities (31,383) Deferred tax liabilities (34,256) Other long-term liabilities (414) Total purchase price allocation $ 876,091 The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 252,900 14 Other intangible assets 4,900 2 Backlog 8,900 1 Total definite-lived intangible assets $ 266,700 13 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s Manufacturing business from new customers introduced to Cognate and the assembled workforce of the acquired business. The goodwill attributable to Cognate is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $11.2 million and $18.4 million for the three and six months ended June 26, 2021 , respectively, which were included in Selling, general and administrative expenses within t he unaudited condensed consolidated statements of income. Beginning on March 29, 2021, Cognate has been included in the operating results of the Company. Cognate revenue and operating income during the three months ended June 26, 2021 was $34.8 million and $1.1 million, respectively. The following selected unaudited pro forma consolidated results of operations are presented as if the Cognate acquisition had occurred as of the beginning of the p eriod immediately preceding the period of acquisition, which is December 29, 2019, after giving effect to certain adjustments. For t he six months ended June 26, 2021, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $9.5 million, additional interest expense on borrowing of $2.2 million, elimi nation of intercompany activity and other one-time costs, and the tax impacts of these adjustments. For t he six months ended June 27, 2020, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $10.2 million, additional interest expense on borrowing of $4.1 million, elimi nation of intercompany activity and other one-time costs, and the tax impacts of these adjustments. Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) (unaudited) Revenue $ 914,607 $ 706,250 $ 1,767,096 $ 1,434,708 Net income attributable to common shareholders 96,365 74,408 138,712 85,249 These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition. Distributed Bio, Inc. On December 31, 2020, the Company acquired Distributed Bio, Inc. (Distributed Bio), a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. The acquisition of Distributed Bio expands the Company’s capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development. The preliminary purchase price of Distributed Bio was $97.0 million, net of $0.8 million in cash, subject to certain post-closing adjustments that may change the purchase price. The total consideration includes $80.8 million cash paid, settlement of $3.0 million in convertible promissory notes previously invested by the Company during prior fiscal years, and $14.0 million of contingent consideration, which is estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $21.0 million based on future performance and milestone achievements over a one-year period). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. The preliminary purchase price allocation of $97.0 million, net of $0.8 million of cash acquired was as follows: December 31, 2020 (in thousands) Trade receivables $ 2,722 Other current assets (excluding cash) 221 Property, plant and equipment 2,382 Goodwill 71,585 Definite-lived intangible assets 24,540 Other long-term assets 2,055 Current liabilities (2,823) Deferred tax liabilities (2,529) Other long-term liabilities (1,123) Total purchase price allocation $ 97,030 The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 16,080 9 Developed technology 3,940 5 Other intangible assets 4,520 4 Total definite-lived intangible assets $ 24,540 7 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA business from new customers introduced to Distributed Bio and the assembled workforce of the acquired business. The goodwill attributable to Distributed Bio is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $0.2 million and $0.9 million for the three and six months ended June 26, 2021 , respectively, which were included in Selling, general and administrative expenses within t he unaudited condensed consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been included because Distributed Bio 's financial results are not significant when compared to the Company’s consolidated financial results. Cellero, LLC On August 6, 2020, the Company acquired Cellero, LLC (Cellero), a provider of cellular products for cell therapy developers and manufacturers worldwide. The addition of Cellero enhances the Company’s unique, comprehensive solutions for the high-growth cell therapy market, strengthening the ability to help accelerate clients’ critical programs from basic research and proof-of-concept to regulatory approval and commercialization. It also expands the Company’s access to high-quality, human-derived biomaterials with Cellero’s donor sites in the United States. The purchase price for Cellero of $36.9 million, net of $0.5 million in cash, was funded through available cash. This business is reported as part of the Company’s RMS reportable segment. The purchase price allocation of $36.9 million, net of $0.5 million of cash acquired was as follows: August 6, 2020 (in thousands) Trade receivables $ 1,500 Inventories 551 Other current assets (excluding cash) 182 Property, plant and equipment 1,648 Goodwill 19,457 Definite-lived intangible assets 16,230 Other long-term assets 849 Current liabilities (1,360) Deferred tax liabilities (1,467) Other long-term liabilities (740) Total purchase price allocation $ 36,850 From the date of the acquisition through June 26, 2021, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 14,740 13 Other intangible assets 1,490 3 Total definite-lived intangible assets $ 16,230 12 The goodwill resulting from the transaction, $10.8 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s RMS business from customers introduced through Cellero and the assembled workforce of the acquired business. The Company incurred integration costs in connection with the acquisition of $0.2 million and $0.6 million for the three and six months ended June 26, 2021, respectively, which were included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been included because Cellero's financial results are not significant when compared to the Company’s consolidated financial results. HemaCare Corporation On January 3, 2020, the Company acquired HemaCare Corporation (HemaCare), a business specializing in the production of human-derived cellular products for the cell therapy market. The acquisition of HemaCare expands the Company’s comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human derived cellular products to better support clients’ cell therapy programs. The purchase price of HemaCare was $376.7 million, net of $3.1 million in cash, which was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s RMS reportable segment. The purchase price allocation of $376.7 million, net of $3.1 million of cash acquired was as follows: January 3, 2020 (in thousands) Trade receivables $ 6,451 Inventories 8,468 Other current assets (excluding cash) 3,494 Property, plant and equipment 10,033 Goodwill 210,196 Definite-lived intangible assets 183,540 Other long-term assets 5,920 Current liabilities (5,188) Deferred tax liabilities (38,529) Other long-term liabilities (7,664) Total purchase price allocation $ 376,721 From the date of the acquisition through December 26, 2020, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 170,390 19 Trade name 7,330 10 Other intangible assets 5,820 3 Total definite-lived intangible assets $ 183,540 18 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s RMS business from customers introduced through HemaCare and the assembled workforce of the acquired business. The goodwill attributable to HemaCare is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $0.3 million and $0.1 million for the three months ended June 26, 2021 and June 27, 2020, respectively, which were included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. The Company incurred transaction and integration costs in connection with the acquisition of $0.4 million and $5.8 million for the six months ended June 26, 2021 and June 27, 2020, respectively, which were included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. The following selected unaudited pro forma consolidated results of operations are presented as if the HemaCare acquisition had occurred as of the beginning of the p eriod immediately preceding the period of acquisition, which is December 30, 2018, after giving effect to certain adjustments. For t he six months ended June 27, 2020, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $0.4 million, elimi nation of intercompany activity and other one-time costs, and the tax impacts of these adjustments. June 27, 2020 Three Months Ended Six Months Ended (unaudited) (unaudited) Revenue $ 682,584 $ 1,389,661 Net income attributable to common shareholders 67,383 123,088 These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition. Other Acquisition

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	6 Months Ended
REVENUE FROM CONTRACTS WITH CUSTOMERS	Jun. 26, 2021
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 66,334 $ 57,357 $ 131,230 $ 117,398 Services and products transferred at a point in time 110,360 59,192 222,374 145,147 Total RMS revenue 176,694 116,549 353,604 262,545 DSA Services and products transferred over time 539,790 442,447 1,040,258 881,011 Services and products transferred at a point in time 304 117 1,014 236 Total DSA revenue 540,094 442,564 1,041,272 881,247 Manufacturing Services and products transferred over time 95,974 41,317 146,542 78,631 Services and products transferred at a point in time 101,845 82,154 197,755 167,220 Total Manufacturing revenue 197,819 123,471 344,297 245,851 Total revenue $ 914,607 $ 682,584 $ 1,739,173 $ 1,389,643 RMS The RMS business generates revenue through the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and management of clients’ research operations. Revenue from the sale of research models and products is recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the shipping terms of a contract. Revenue generated from research models services is recognized over time and is typically based on a right-to-invoice measure of progress (output method) as invoiced amounts correspond directly to the value of the Company’s performance to date. DSA The DSA business provides a full suite of integrated drug discovery services directed at the identification, screening and selection of a lead compound for drug development and offers a full range of safety assessment services including bioanalysis, drug metabolism, pharmacokinetics, toxicology and pathology. DSA services revenue is generally recognized over time using the cost-to-cost or right to invoice measures of progress, primarily representing fixed fee service contracts and per unit service contracts, respectively. Manufacturing The Manufacturing business includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics as well as contract development and manufacturing; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Species identification service revenue is generally recognized at a point in time as identifications are completed by the Company. Biologics service revenue is generally recognized over time using the cost-to-cost measure of progress. Microbial Solutions and Avian product sales are generally recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Transaction Price Allocated to Future Performance Obligations The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of June 26, 2021. Excluded from the disclosure is the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed and (iii) service revenue recognized in accordance with ASC 842, “Leases” (see additional disclosure for Other Performance Obligations). The Company has assessed future performance obligations with respect to the COVID-19 pandemic uncertainties and believes there is an insignificant impact on the ability to meet future performance obligations and the amount of revenue to be recognize d. The following table inclu des estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of June 26, 2021: Revenue Expected to be Recognized in Future Periods Less than 1 Year 1 to 3 Years 4 to 5 Years Beyond 5 Years Total (in thousands) DSA $ 287,948 $ 211,364 $ 8,893 $ 359 $ 508,564 Manufacturing 7,561 923 — — 8,484 Total $ 295,509 $ 212,287 $ 8,893 $ 359 $ 517,048 Contract Balances from Contracts with Customers The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the unaudited condensed consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: June 26, 2021 December 26, 2020 (in thousands) Balances from contracts with customers: Client receivables $ 480,533 $ 489,042 Contract assets (unbilled revenue) 171,032 135,400 Contract liabilities (current and long-term deferred revenue) 249,585 227,417 Contract liabilities (customer contract deposits) 44,981 42,244 When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $19 million and $16 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying unaudited condensed consolidated balance sheets as of June 26, 2021 and December 26, 2020, respectively. Advanced client payments of approximately $45 million and $42 million have been presented as customer contract deposits within other current liabilities in the accompanying unaudited condensed consolidated balance sheets as of June 26, 2021 and December 26, 2020, respectively. Other changes in the contract asset and the contract liability balances during the six months ended June 26, 2021 and June 27, 2020 were as follows: (i) Changes due to business combinations: See Note 2. “Business Combinations” for the Company’s recent acquisitions. (ii) Cumulative catch-up adjustments to revenue that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration is constrained), or a contract modification: During the six months ended June 26, 2021 and June 27, 2020, immaterial cumulative catch-up adjustments to revenue were recorded. (iii) A change in the time frame for a right to consideration to become unconditional (that is, for a contract asset to be recorded as a client receivable): Approximately 80% of unbilled revenue as of December 26, 2020, which was $135 million, was billed during the six months ended June 26, 2021. Approximately 75% of unbilled revenue as of December 28, 2019, which was $122 million, was billed during the six months ended June 27, 2020. (iv) A change in the time frame for a performance obligation to be satisfied (that is, for the recognition of revenue arising from a contract liability): Approximately 75% of contract liabilities as of December 26, 2020, which was $227 million, were recognized as revenue during the six months ended June 26, 2021. Approximately 75% of contract liabilities as of December 28, 2019, which was $193 million, were recognized as revenue during the six months ended June 27, 2020. Other Performance Obligation s As part of the Company’s service offerings, primarily in the Manufacturing segment, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. For the three and six months ended June 26, 2021, the Company recognized lease revenue of $6.3 million, which is recorded within service revenue, which is transferred over time, within the unaudited condensed consolidated statements of income. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the unaudited condensed consolidated financial statements.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
SEGMENT INFORMATION	Jun. 26, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company’s three reportable segments are RMS, DSA, and Manufacturing. The following table presents revenue and other financial information by reportable segment: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS Revenue $ 176,694 $ 116,549 $ 353,604 $ 262,545 Operating income 42,580 3,844 87,515 31,217 Depreciation and amortization 9,844 9,126 19,523 17,878 Capital expenditures 8,512 6,621 11,495 12,033 DSA Revenue $ 540,094 $ 442,564 $ 1,041,272 $ 881,247 Operating income 104,514 72,241 195,463 144,524 Depreciation and amortization 43,588 41,101 88,196 82,431 Capital expenditures 20,473 16,175 37,513 30,904 Manufacturing Revenue $ 197,819 $ 123,471 $ 344,297 $ 245,851 Operating income 56,717 42,930 106,154 84,042 Depreciation and amortization 13,952 6,236 20,521 12,602 Capital expenditures 13,602 3,037 20,712 8,198 Reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows: Operating Income Depreciation and Amortization Capital Expenditures June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Three Months Ended: Total reportable segments $ 203,811 $ 119,015 $ 67,384 $ 56,463 $ 42,587 $ 25,833 Unallocated corporate (66,261) (42,247) 722 745 3,844 967 Total consolidated $ 137,550 $ 76,768 $ 68,106 $ 57,208 $ 46,431 $ 26,800 Six Months Ended: Total reportable segments $ 389,132 $ 259,783 $ 128,240 $ 112,911 $ 69,720 $ 51,135 Unallocated corporate (127,879) (88,734) 1,373 1,557 4,741 1,386 Total consolidated $ 261,253 $ 171,049 $ 129,613 $ 114,468 $ 74,461 $ 52,521 Revenue for each significant product or service offering is as follows: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS $ 176,694 $ 116,549 $ 353,604 $ 262,545 DSA 540,094 442,564 1,041,272 881,247 Manufacturing 197,819 123,471 344,297 245,851 Total revenue $ 914,607 $ 682,584 $ 1,739,173 $ 1,389,643 A summary of unallocated corporate expense consists of the following: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Stock-based compensation $ 10,417 $ 8,203 $ 18,059 $ 14,907 Compensation, benefits, and other employee-related expenses 25,924 20,749 53,286 42,729 External consulting and other service expenses 6,301 4,917 13,657 7,386 Information technology 4,117 4,235 8,212 7,951 Depreciation 722 745 1,373 1,557 Acquisition and integration 15,036 869 25,596 7,852 Other general unallocated corporate 3,744 2,529 7,696 6,352 Total unallocated corporate expense $ 66,261 $ 42,247 $ 127,879 $ 88,734 Other general unallocated corporate expense consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: June 26, 2021 $ 491,619 $ 275,706 $ 90,565 $ 55,133 $ 1,584 $ 914,607 June 27, 2020 382,918 190,935 71,543 35,965 1,223 682,584 Six Months Ended: June 26, 2021 $ 940,101 $ 513,241 $ 167,672 $ 114,579 $ 3,580 $ 1,739,173 June 27, 2020 789,630 381,197 148,176 67,794 2,846 1,389,643 Included in the Other category above are operations located in Brazil and Israel. Revenue represents sales originating in entities physically located in the identified geographic area.

SUPPLEMENTAL BALANCE SHEET INFO

SUPPLEMENTAL BALANCE SHEET INFORMATION	6 Months Ended
SUPPLEMENTAL BALANCE SHEET INFORMATION	Jun. 26, 2021
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	SUPPLEMENTAL BALANCE SHEET INFORMATION The composition of trade receivables and contract assets, net is as follows: June 26, 2021 December 26, 2020 (in thousands) Client receivables $ 480,533 $ 489,042 Unbilled revenue 171,032 135,400 Total 651,565 624,442 Less: Allowance for doubtful accounts (7,538) (6,702) Trade receivables and contract assets, net $ 644,027 $ 617,740 The composition of inventories is as follows: June 26, 2021 December 26, 2020 (in thousands) Raw materials and supplies $ 32,071 $ 28,317 Work in process 28,314 36,755 Finished products 133,956 120,623 Inventories $ 194,341 $ 185,695 The composition of other current assets is as follows: June 26, 2021 December 26, 2020 (in thousands) Prepaid income tax $ 117,811 $ 68,462 Short-term investments 1,037 1,024 Restricted cash 3,118 3,074 Other current assets $ 121,966 $ 72,560 The composition of other assets is as follows: June 26, 2021 December 26, 2020 (in thousands) Venture capital investments $ 174,420 $ 197,100 Strategic equity investments 39,342 24,704 Life insurance policies 48,715 43,827 Other long-term income tax assets 23,153 23,485 Restricted cash 1,403 1,621 Long-term pension assets 34,362 31,915 Other 36,399 29,974 Other assets $ 357,794 $ 352,626 The composition of other current liabilities is as follows: June 26, 2021 December 26, 2020 (in thousands) Current portion of operating lease right-of-use liabilities $ 31,741 $ 24,674 Accrued income taxes 39,066 24,884 Customer contract deposits 44,981 42,244 Other 16,511 10,675 Other current liabilities $ 132,299 $ 102,477 The composition of other long-term liabilities is as follows: June 26, 2021 December 26, 2020 (in thousands) U.S. Transition Tax $ 43,057 $ 48,781 Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plan 75,221 74,233 Long-term deferred revenue 18,256 19,475 Other 70,843 62,726 Other long-term liabilities $ 207,377 $ 205,215

VENTURE CAPITAL AND STRATEGIC E

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	6 Months Ended
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	Jun. 26, 2021
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Venture capital investments were $174.4 million and $197.1 million as of June 26, 2021 and December 26, 2020, respectively. The Company’s total commitment to the venture capital funds as of June 26, 2021 was $149.5 million, of which the Company funded $105.2 million through that date. The Company received distributions totaling $18.2 million and $2.4 million for the three months ended June 26, 2021 and June 27, 2020, respectively. The Company received distributions totaling $27.5 million and $3.3 million for the six months ended June 26, 2021 and June 27, 2020, respectively. The Company recognized net gains on venture capital investments of $11.0 million for the three months ended June 26, 2021, driven primarily by increases in fair value of private investments, and $23.9 million for the three months ended June 27, 2020, driven primarily by increases in fair value of public investments. The Company recognized net losses on venture capital investments of $5.3 million for the six months ended June 26, 2021, driven by the decrease in the fair value of publicly-held investments offset by increases from private investments, and net gains of $11.9 million for the six months ended June 27, 2020, predominantly driven by increases in fair value of public investments. The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. Strategic equity investments were $39.3 million and $24.7 million as of June 26, 2021 and December 26, 2020, respectively. The Company recognized insignificant gains and losses for the three and six months ended June 26, 2021 and June 27, 2020.

FAIR VALUE

FAIR VALUE	6 Months Ended
FAIR VALUE	Jun. 26, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy: • Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access, • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates, • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the six months ended June 26, 2021 and June 27, 2020, there were no transfers between levels. Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows: • Cash equivalents - Valued at market prices determined through third-party pricing services; • Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates; • Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments; • Debt instruments - The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and • Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes. Assets and liabilities measured at fair value on a recurring basis are summarized below: June 26, 2021 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 1,592 $ — $ 1,592 Other assets: Life insurance policies — 40,652 — 40,652 Total assets measured at fair value $ — $ 42,244 $ — $ 42,244 Other current liabilities measured at fair value: Contingent consideration $ — $ — $ 23,531 $ 23,531 Other long-term liabilities measured at fair value: Contingent consideration — — 13,776 13,776 Total liabilities measured at fair value $ — $ — $ 37,307 $ 37,307 December 26, 2020 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 2,273 $ — $ 2,273 Other assets: Life insurance policies — 35,770 — 35,770 Total assets measured at fair value $ — $ 38,043 $ — $ 38,043 Other liabilities measured at fair value: Contingent consideration $ — $ — $ 2,328 $ 2,328 Total liabilities measured at fair value $ — $ — $ 2,328 $ 2,328 Contingent Consideration The following table provides a rollforward of the contingent consideration related to the Company’s business combinations. See Note 2, “Business Combinations.” Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Beginning balance $ 2,328 $ 712 Additions 37,983 2,131 Payments (2,889) (230) Adjustment of previously recorded contingent liability — (468) Foreign currency (115) (3) Ending balance $ 37,307 $ 2,142 The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, discount rates, and risk-free rates. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively. Debt Instruments The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy. The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below: June 26, 2021 December 26, 2020 Book Value Fair Value Book Value Fair Value 5.5% Senior Notes due 2026 $ — $ — $ 500,000 $ 523,100 4.25% Senior Notes due 2028 500,000 516,850 500,000 523,750 3.75% Senior Notes due 2029 500,000 505,000 — — 4.0% Senior Notes due 2031 500,000 515,000 — —

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Jun. 26, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 26, 2020 Acquisitions Foreign Exchange June 26, 2021 (in thousands) RMS $ 287,759 $ — $ 97 $ 287,856 DSA 1,378,130 122,227 994 1,501,351 Manufacturing 143,279 603,379 4,202 750,860 Goodwill $ 1,809,168 $ 725,606 $ 5,293 $ 2,540,067 The increase in goodwill during the six months ended June 26, 2021 related primarily to the acquisitions of Cognate in the Manufacturing reportable segment and Distributed Bio and Retrogenix in the DSA reportable segment. Intangible Assets, Net The following table displays intangible assets, net by major class: June 26, 2021 December 26, 2020 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 9,844 $ (4,291) $ 5,553 $ 29,233 $ (29,233) $ — Technology 138,207 (89,911) 48,296 130,907 (81,305) 49,602 Trademarks and trade names 13,568 (2,704) 10,864 15,870 (5,648) 10,222 Other 33,327 (5,589) 27,738 20,903 (14,633) 6,270 Other intangible assets 194,946 (102,495) 92,451 196,913 (130,819) 66,094 Client relationships 1,431,254 (466,930) 964,324 1,137,331 (415,826) 721,505 Intangible assets $ 1,626,200 $ (569,425) $ 1,056,775 $ 1,334,244 $ (546,645) $ 787,599 The increase in intangible assets, net during the six months ended June 26, 2021 related primarily to the acquisitions of Cognate, Distributed Bio and Retrogenix.

LONG-TERM DEBT AND FINANCE LEAS

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS	6 Months Ended
LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS	Jun. 26, 2021
Debt Disclosure [Abstract]
LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS	LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS Long-term debt, net and finance leases consists of the following: June 26, 2021 December 26, 2020 (in thousands) Term loans $ — $ 146,875 Revolving facility 1,225,383 814,752 5.5% Senior Notes due 2026 — 500,000 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 — 4.0% Senior Notes due 2031 500,000 — Other debt 372 3,457 Finance leases (Note 16) 29,153 29,047 Total debt and finance leases 2,754,908 1,994,131 Less: Current portion of long-term debt 108 47,196 Current portion of finance leases (Note 16) 2,913 3,018 Current portion of long-term debt and finance leases 3,021 50,214 Long-term debt and finance leases 2,751,887 1,943,917 Debt discount and debt issuance costs (24,647) (14,346) Long-term debt, net and finance leases $ 2,727,240 $ 1,929,571 As of June 26, 2021 and December 26, 2020, the weighted average interest rate on the Company’s debt was 2.74% and 3.11%, respectively. Term L oans and Revolving Facility (Credit Facility) As of and for the three months ended March 27, 2021, the Company had a credit facility consisting of a $750 million term loan and a $2.05 billion multi-currency revolving facility. The term loan facility matured in 19 quarterly installments with the last installment due March 26, 2023. During the three months ended March 27, 2021, the Company prepaid the remaining amount of the term loan, or $146.9 million, with proceeds from an unregistered private offering (see 2029 and 2031 Senior Notes below). The revolving facility matured on March 26, 2023, and required no scheduled payment before that date. Approximately $0.2 million of deferred financing costs were expensed upon prepayment of the term loan. During the three months ended June 26, 2021, the Company amended and restated the Credit Facility increasing the capacity of the revolving credit facility and extending the maturity date to April 2026, which requires no scheduled payment before that date. The amended and restated Credit Facility provides for a $3.0 billion multi-currency revolving facility. No additional term loan was borrowed. Amendments were made in connection with the prospective discontinuation of LIBOR and other changes in law since the execution of the Company’s existing credit agreement and makes other amendments to certain other covenants and terms. The interest rates applicable to the amended and restated revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at the Company’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted LIBOR rate plus 1%) or the adjusted LIBOR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon the Company’s leverage ratio. The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0. As of June 26, 2021, the Company was compliant with all financial covenants under the Credit Agreement. The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company. During the six months ended June 26, 2021 and June 27, 2020, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Company’s Credit Facility, which were $400 million each. This resulted in foreign currency losses recognized in Other income, net of $18.3 million and $4.2 million during the six months ended June 26, 2021 and June 27, 2020, respectively, related to the remeasurement of the underlying debt. The Company entered into foreign exchange forward contracts to limit its foreign currency ex posures related to these borrowings and recognized gains of $19.3 million a nd $6.1 million during the six months ended June 26, 2021 and June 27, 2020, respectively, within Interest expense. As of June 26, 2021, the Company did not have any outstanding borrowings in a currency different than its respective functional currency. See Note 14, “Foreign Currency Contracts”, for further discussion. Base Indenture for Senior Notes The Company enters into certain indentures in order to issue senior notes and is subject to certain affirmative and negative covenants. The Company has the following Senior Notes in the current and prior fiscal periods. 2026 Senior Notes In fiscal year 2018, the Company issued $500 million of 5.5% Senior Notes due in 2026 (2026 Senior Notes) in an unregistered offering. Interest on the 2026 Senior Notes was payable semi-annually on April 1 and October 1. During the three months ended March 27, 2021, the Company prepaid the $500 million 2026 Seniors Notes along with $21 million of related debt extinguishment costs and $13 million of accrued interest using proceeds from additional senior notes issued on the same day (see 2029 and 2031 Senior Notes). The payment of the 2026 Senior Notes was accounted for as a debt extinguishment. Approximately $21 million of debt extinguishment costs and $5 million of deferred financing costs write-offs were recorded in Interest expense during the three months ended March 27, 2021. 2028 Senior Notes In fiscal year 2019, the Company issued $500 million of 4.25% Senior Notes due in 2028 (2028 Senior Notes) in an unregistered offering. Interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1. 2029 Senior Notes and 2031 Senior Notes In the three months ended March 27, 2021, the Company issued $1 billion of debt split between $500 million of 3.75% Senior Notes due in 2029 (2029 Senior Notes), and $500 million of 4.00% Senior Notes due in 2031 (2031 Senior Notes), in an unregistered offering. Interest on the 2029 and 2031 Senior Notes is payable semi-annually on March 15 and September 15. Approximately $10 million of deferred financing costs were capitalized as part of this debt issuance. Proceeds from the 2029 and 2031 Senior Notes were used as follows: prepay the $500 million 2026 Senior Notes, $21 million of debt extinguishment costs, and $13 million of accrued interest; prepay the $146.9 million remaining term loan; pay down $135 million of the revolving facility; and pay for a portion of the Cognate acquisition, which occurred on March 29, 2021. Principal Maturities Principal maturities of existing debt, giving effect to the amended and restated Credit Agreement, for the periods set forth in the table below, are as follows: Principal (in thousands) 2021 (excluding the six months ended June 26, 2021) $ 108 2022 — 2023 — 2024 264 2025 — Thereafter 2,725,383 Total $ 2,725,755 Letters of Credit As of June 26, 2021 and December 26, 2020, the Company had $16.7 million and $16.0 million, respectively, in outstanding letters of credit.

EQUITY AND NONCONTROLLING INTER

EQUITY AND NONCONTROLLING INTERESTS	6 Months Ended
EQUITY AND NONCONTROLLING INTERESTS	Jun. 26, 2021
Equity [Abstract]
EQUITY AND NONCONTROLLING INTERESTS	EQUITY AND NONCONTROLLING INTERESTS Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Numerator: Net income $ 89,916 $ 67,668 $ 153,851 $ 118,505 Less: Net income attributable to noncontrolling interests 1,468 233 3,873 301 Net income attributable to common shareholders $ 88,448 $ 67,435 $ 149,978 $ 118,204 Denominator: Weighted-average shares outstanding - Basic 50,297 49,553 50,138 49,371 Effect of dilutive securities: Stock options, restricted stock units and performance share units 1,037 693 1,087 747 Weighted-average shares outstanding - Diluted 51,334 50,246 51,225 50,118 Options to purchase 0.2 million and 0.6 million shares for the three months ended June 26, 2021 and June 27, 2020, respectively, as well as a non-significant number of restricted stock units (RSUs) and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase 0.2 million and 0.6 million shares for the six months ended June 26, 2021 and June 27, 2020, respectively, as well as a non-significant number of restricted stock units (RSUs) and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted-average shares outstanding for the six months ended June 26, 2021 and June 27, 2020 excluded the impact of 0.7 million and 0.9 million shares of non-vested RSUs and PSUs, respectively. Treasury Shares During the six months ended June 26, 2021 and June 27, 2020, the Company did not repurchase any shares under its authorized stock repurchase program. As of June 26, 2021, the Company had $129.1 million remaining on the authorized stock repurchase program. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. During the six months ended June 26, 2021 and June 27, 2020, the Company acquired 0.1 million shares for $40.3 million and 0.1 million shares for $23.8 million, respectively, from such netting. Accumulated Other Comprehensive Income (Loss) Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 26, 2020 $ (73,884) $ (64,990) $ (138,874) Other comprehensive income before reclassifications 30,296 — 30,296 Amounts reclassified from accumulated other comprehensive income — 1,981 1,981 Net current period other comprehensive income 30,296 1,981 32,277 Income tax expense 933 491 1,424 June 26, 2021 $ (44,521) $ (63,500) $ (108,021) Nonredeemable Noncontrolling Interest The Company has an investment in an entity whose financial results are consolidated in the Company’s unaudited condensed consolidated financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying unaudited condensed consolidated balance sheets. The activity within the nonredeemable noncontrolling interest was not significant during the three and six months ended June 26, 2021 and June 27, 2020. Redeemable Noncontrolling Interests The Company has a 92% equity interest in Vital River with an 8% redeemable noncontrolling interest. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. These rights are exercisable beginning in 2022 and are accelerated in certain events. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value ($20.9 million as of June 26, 2021) and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 8% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 8% equity interest is not limited. As part of the Citoxlab acquisition in 2019, the Company acquired an approximate 90% equity interest in a subsidiary that was fully consolidated under the voting interest model, which included an approximate 10% redeemable noncontrolling interest. In February 2020, the Company purchased the remaining approximate 10% noncontrolling interest for approximately $4 million and assumption of a contingent consideration liability payable to the former shareholders. See Note 7. “Fair Value”. In 2019, the Company acquired an 80% equity interest in a subsidiary that is fully consolidated under the voting interest model, which includes a 20% redeemable noncontrolling interest. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 20% equity interest at its appraised value. These rights are exercisable beginning in 2022. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest or a predetermined floor value. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 20% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 20% equity interest is not limited. The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests: Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Beginning balance $ 25,499 $ 28,647 Adjustment to Vital River redemption value 2,341 — Purchase of a 10% redeemable noncontrolling interest — (3,732) Net income (loss) attributable to noncontrolling interests 2,599 (538) Foreign currency translation 360 (493) Ending balance $ 30,799 $ 23,884

INCOME TAXES

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 26, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rates for the three months ended June 26, 2021 and June 27, 2020 were 29.5% and 19.4%, respectively. The Company’s effective tax rates for the six months ended June 26, 2021 and June 27, 2020 were 20.6% and 15.0%, respectively. For the first half of 2021, the increases in the effective tax rates from the prior year periods were primarily attributable to deferred tax impacts of tax law changes enacted in the three months ended June 26, 2021 and higher non-deductible transaction costs, partially offset by increased tax benefit from stock-based compensation deductions in the first half of 2021 compared to the corresponding period in 2020. For the three months ended June 26, 2021, the Company’s unrecognized tax benefits increased by $1.6 million to $26.9 million, primarily due to uncertainties pertaining to acquisitions in the period, an additional quarter of Canadian Scientific Research and Experimental Development Credit reserves, partially offset by audit settlements. For the three months ended June 26, 2021, the unrecognized income tax benefits that would impact the effective tax rate increased by $2.1 million to $24.6 million, for the same reasons discussed above. The accrued interest on unrecognized tax benefits was $2.0 million at June 26, 2021. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by approximately $1.1 million over the next twelve-month period, primarily due to the lapse of statute of limitations. The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., Canada, the U.K., France, Germany, and China. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2017. The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, France, Germany, and India. The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.

PENSION AND OTHER POST-RETIREME

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS	6 Months Ended
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS	Jun. 26, 2021
Retirement Benefits [Abstract]
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS	PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS The following table provides the components of net periodic cost for the Company’s pension, deferred compensation and executive supplemental life insurance retirement plans: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Service cost $ 911 $ 798 $ 1,822 $ 1,595 Interest cost 1,344 2,354 2,688 4,709 Expected return on plan assets (1,983) (2,982) (3,967) (5,963) Amortization of prior service cost (credit) (128) (126) (256) (251) Amortization of net loss 1,110 1,586 2,220 3,172 Other adjustments (572) 125 (572) 250 Net periodic cost $ 682 $ 1,755 $ 1,935 $ 3,512 Service cost is recorded as an operating expense within the accompanying unaudited condensed consolidated statements of income. All other components of net periodic costs are recorded in Other expense, net in the accompanying unaudited condensed consolidated statements of income. The net periodic cost for the Company’s other post-retirement benefit plan for the three and six months ended June 26, 2021 and June 27, 2020 was not significant.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 26, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, RSUs, and PSUs. The following table provides stock-based compensation by the financial statement line item in which it is reflected: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Cost of revenue $ 3,012 $ 2,320 $ 5,725 $ 4,355 Selling, general and administrative 14,065 10,823 24,541 19,748 Stock-based compensation, before income taxes 17,077 13,143 30,266 24,103 Provision for income taxes (2,465) (1,988) (4,452) (3,539) Stock-based compensation, net of income taxes $ 14,612 $ 11,155 $ 25,814 $ 20,564 During the six months ended June 26, 2021, the Company granted stock options representing 0.2 million common shares with a per-share weighted-average grant date fair value of $108.52, RSUs representing 0.1 million common shares with a per-share weighted-average grant date fair value of $337.45, and PSUs representing 0.1 million common shares with a per-share weighted-average grant date fair value of $407.76. The maximum number of common shares to be issued upon vesting of PSUs granted during the six months ended June 26, 2021 is 0.1 million.

FOREIGN CURRENCY CONTRACTS

FOREIGN CURRENCY CONTRACTS	6 Months Ended
FOREIGN CURRENCY CONTRACTS	Jun. 26, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FOREIGN CURRENCY CONTRACTS	FOREIGN CURRENCY CONTRACTS Cross currency loans The Company periodically enters into foreign exchange forward contracts to limit its foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Company’s Credit Facility. These contracts are not designated as hedging instruments. Any gains or losses on these forward contracts are recognized immediately within Interest expense in the unaudited condensed consolidated statements of income. The Company had no open forward contracts related to a U.S. dollar denominated loan borrowed by a non-U.S. Euro functional currency a t June 26, 2021 or December 26, 2020. The following table summarizes the effect of the foreign exchange forward contracts entered into to limit the Company’s foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility on the Company’s unaudited condensed consolidated statements of income: June 26, 2021 June 27, 2020 Location of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) (in thousands) Three Months Ended: Interest expense $ (16,190) $ 5,355 $ (19,352) $ — Six Months Ended: Interest expense $ (45,909) $ 19,332 $ (34,419) $ 6,067 Intercompany loans The Company periodically enters into foreign exchange forward contracts to limit its foreign currency exposure related to certain intercompany loans. These contracts are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other income (expense), net and are largely offset by the remeasurement of the underlying intercompany loans. The Company did not enter into foreign currency forward contracts related to certain intercompany loans during 2021 and 2020. The Company settled one foreign currency forward contract related to certain intercompany loans in 2020, and recognized an immaterial loss during the six months ended June 27, 2020 recognized in Other expense, net.

RESTRUCTURING AND ASSET IMPAIRM

RESTRUCTURING AND ASSET IMPAIRMENTS	6 Months Ended
RESTRUCTURING AND ASSET IMPAIRMENTS	Jun. 26, 2021
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET IMPAIRMENTS	RESTRUCTURING AND ASSET IMPAIRMENTSGlobal Restructuring Initiatives In recent fiscal years, the Company has undertaken productivity improvement initiatives within all reportable segments at various locations across the U.S., Canada, Europe, and China. This includes workforce right-sizing and scalability initiatives, resulting in severance and transition costs; and cost related to the consolidation of facilities, resulting in asset impairment and accelerated depreciation charges The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income. June 26, 2021 June 27, 2020 Severance and Transition Costs Asset Impairments and Other Costs Total Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Three Months Ended: Cost of services provided and products sold (excluding amortization of intangible assets) $ 393 $ — $ 393 $ 3,299 $ 30 $ 3,329 Selling, general and administrative 1,070 146 1,216 2,089 2,933 5,022 Total $ 1,463 $ 146 $ 1,609 $ 5,388 $ 2,963 $ 8,351 Six Months Ended: Cost of services provided and products sold (excluding amortization of intangible assets) $ 916 $ 40 $ 956 $ 3,545 $ 259 $ 3,804 Selling, general and administrative 1,109 293 1,402 2,172 2,933 5,105 Total $ 2,025 $ 333 $ 2,358 $ 5,717 $ 3,192 $ 8,909 The following table presents restructuring costs by reportable segment for these productivity improvement initiatives: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS $ — $ 769 $ 7 $ 759 DSA 1,074 6,186 1,633 6,498 Manufacturing 535 1,396 869 1,652 Unallocated corporate — — (151) — Total $ 1,609 $ 8,351 $ 2,358 $ 8,909 Rollforward of restructuring activities The following table provides a rollforward for all of the Company’s severance and transition costs and certain lease related costs related to all restructuring activities: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Beginning balance $ 2,221 $ 2,531 $ 5,816 $ 6,405 Expense (excluding non-cash charges) 1,609 6,357 2,358 6,874 Payments / utilization (999) (1,674) (3,465) (5,917) Other non-cash adjustments — — (1,831) — Foreign currency adjustments 11 (15) (36) (163) Ending balance $ 2,842 $ 7,199 $ 2,842 $ 7,199

LEASES

LEASES	6 Months Ended
LEASES	Jun. 26, 2021
Leases [Abstract]
LEASES	LEASES Operating and Finance Leases Right-of-use lease assets and lease liabilities are reported in the Company’s unaudited condensed consolidated balance sheets as follows: June 26, 2021 December 26, 2020 (in thousands) Operating leases Operating lease right-of-use assets, net $ 276,820 $ 178,220 Other current liabilities $ 31,741 $ 24,674 Operating lease right-of-use liabilities 239,484 155,595 Total operating lease liabilities $ 271,225 $ 180,269 Finance leases Property, plant and equipment, net $ 31,684 $ 31,614 Current portion of long-term debt and finance leases $ 2,913 $ 3,018 Long-term debt, net and finance leases 26,240 26,029 Total finance lease liabilities $ 29,153 $ 29,047 The components of operating and finance lease costs were as follows: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Operating lease costs $ 11,025 $ 7,893 $ 20,376 $ 15,971 Finance lease costs: Amortization of right-of-use assets 840 937 1,688 1,888 Interest on lease liabilities 327 323 655 663 Short-term lease costs 1,332 525 2,282 1,114 Variable lease costs 751 1,067 1,635 2,112 Sublease income (580) (190) (954) (776) Total lease costs $ 13,695 $ 10,555 $ 25,682 $ 20,972 Other information related to leases was as follows: Supplemental cash flow information Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 18,578 $ 14,149 Operating cash flows from finance leases 656 663 Finance cash flows from finance leases 1,705 2,467 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 107,306 $ 46,493 Right-of-use lease assets obtained in exchange for new finance lease liabilities 842 735 Lease term and discount rate As of As of June 26, 2021 June 27, 2020 Weighted-average remaining lease term (in years) Operating lease 9.4 8.4 Finance lease 12.1 12.6 Weighted-average discount rate Operating lease 3.7 % 4.2 % Finance lease 4.4 % 4.5 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. As of June 26, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2021 (excluding the six months ended June 26, 2021) $ 20,787 $ 2,131 2022 39,976 3,912 2023 36,660 3,526 2024 35,208 3,294 2025 33,112 3,012 Thereafter 159,581 22,219 Total minimum future lease payments 325,324 38,094 Less: Imputed interest 54,099 8,941 Total lease liabilities $ 271,225 $ 29,153 Total minimum future lease payments (predominantly operating leases) of approximately $120 million for leases that have not commenced as of June 26, 2021, as the Company does not yet control the underlying assets, are not included in the unaudited condensed consolidated financial statements. These leases are expected to commence between fiscal years 2021 and 2024 with lease terms of approximately 8 to 15 years.
LEASES	LEASES Operating and Finance Leases Right-of-use lease assets and lease liabilities are reported in the Company’s unaudited condensed consolidated balance sheets as follows: June 26, 2021 December 26, 2020 (in thousands) Operating leases Operating lease right-of-use assets, net $ 276,820 $ 178,220 Other current liabilities $ 31,741 $ 24,674 Operating lease right-of-use liabilities 239,484 155,595 Total operating lease liabilities $ 271,225 $ 180,269 Finance leases Property, plant and equipment, net $ 31,684 $ 31,614 Current portion of long-term debt and finance leases $ 2,913 $ 3,018 Long-term debt, net and finance leases 26,240 26,029 Total finance lease liabilities $ 29,153 $ 29,047 The components of operating and finance lease costs were as follows: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Operating lease costs $ 11,025 $ 7,893 $ 20,376 $ 15,971 Finance lease costs: Amortization of right-of-use assets 840 937 1,688 1,888 Interest on lease liabilities 327 323 655 663 Short-term lease costs 1,332 525 2,282 1,114 Variable lease costs 751 1,067 1,635 2,112 Sublease income (580) (190) (954) (776) Total lease costs $ 13,695 $ 10,555 $ 25,682 $ 20,972 Other information related to leases was as follows: Supplemental cash flow information Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 18,578 $ 14,149 Operating cash flows from finance leases 656 663 Finance cash flows from finance leases 1,705 2,467 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 107,306 $ 46,493 Right-of-use lease assets obtained in exchange for new finance lease liabilities 842 735 Lease term and discount rate As of As of June 26, 2021 June 27, 2020 Weighted-average remaining lease term (in years) Operating lease 9.4 8.4 Finance lease 12.1 12.6 Weighted-average discount rate Operating lease 3.7 % 4.2 % Finance lease 4.4 % 4.5 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. As of June 26, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2021 (excluding the six months ended June 26, 2021) $ 20,787 $ 2,131 2022 39,976 3,912 2023 36,660 3,526 2024 35,208 3,294 2025 33,112 3,012 Thereafter 159,581 22,219 Total minimum future lease payments 325,324 38,094 Less: Imputed interest 54,099 8,941 Total lease liabilities $ 271,225 $ 29,153 Total minimum future lease payments (predominantly operating leases) of approximately $120 million for leases that have not commenced as of June 26, 2021, as the Company does not yet control the underlying assets, are not included in the unaudited condensed consolidated financial statements. These leases are expected to commence between fiscal years 2021 and 2024 with lease terms of approximately 8 to 15 years.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 26, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
BASIS OF PRESENTATION (Policies)	Jun. 26, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2020. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.
Use of Estimates	The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The COVID-19 pandemic is dynamic, and its ultimate scope, duration and effects are uncertain. This pandemic has and continues to result in, and any future epidemic or pandemic crises may potentially result in, direct and indirect adverse effects on the Company’s industry and customers, which in turn has (with respect to COVID-19) and may (with respect to future epidemics or crises) impact the Company’s business, results of operations and financial condition. Further, the COVID-19 pandemic may also affect the Company’s operating and financial results in a manner that is not presently known to the Company or that the Company currently does not expect to present significant risks to its operations or financial results. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s condensed consolidated financial statements.
Consolidation	The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Fiscal Period	The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31.
Segment Reporting	The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research Products businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services). Research Products supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification
Newly Adopted and Newly Issued Accounting Pronouncements	In January 2020, the Financial Accounting Standards Board (FASB) issue d ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. This standard became effective for the Company in the three months ended March 27, 2021 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities, the incremental approach for intraperiod tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. This standard became effective for the Company in the three months ended March 27, 2021 and did not have a significant impact on the unaudited condensed consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU, including subsequently issued updates, offers temporary optional expedients and exceptions for applying U.S. GAAP to modifications to agreements such as loans, debt securities, derivatives, and borrowings which reference LIBOR or another reference rate that will partially discontinue after December 31, 2021 and fully cease by June 30, 2023. The expedients and exceptions provided by the standard do not apply to modifications made and hedging relationships entered into or evaluated after that, except for hedging relationships existing as of the phase-out date that an entity has elected certain optional expedients for and are retained through the end of the hedging relationship. The ASU is effective until the replacement for LIBOR is completed. The interest rate on the Company’s revolving credit facility, which was amended and restated in April 2021 (see Note 9. Long-term debt and finance lease obligations) and matures in fiscal year 2026, is linked to LIBOR and alternative interest rates when LIBOR is discontinued. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements and related disclosures, but does not believe there will be a material impact upon adoption.

BUSINESS COMBINATIONS (Tables)

BUSINESS COMBINATIONS (Tables)	6 Months Ended
BUSINESS COMBINATIONS (Tables)	Jun. 26, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Purchase Price Allocation	The preliminary purchase price allocation of $53.1 million, net of $8.5 million of cash acquired was as follows: March 30, 2021 (in thousands) Trade receivables $ 2,266 Other current assets (excluding cash) 209 Property, plant and equipment 400 Goodwill 33,625 Definite-lived intangible assets 22,126 Other long-term assets 1,385 Current liabilities (1,569) Deferred tax liabilities (4,174) Other long-term liabilities (1,205) Total purchase price allocation $ 53,063 The preliminary purchase price allocation of $876.1 million, net of $70.5 million of cash acquired was as follows: March 29, 2021 (in thousands) Trade receivables $ 16,564 Inventories 4,231 Other current assets (excluding cash) 9,840 Property, plant and equipment 52,082 Operating lease right-of-use assets, net 34,349 Goodwill 603,379 Definite-lived intangible assets 266,700 Other long-term assets 6,098 Deferred revenue (18,582) Current liabilities (32,517) Operating lease right-of-use liabilities (31,383) Deferred tax liabilities (34,256) Other long-term liabilities (414) Total purchase price allocation $ 876,091 The preliminary purchase price allocation of $97.0 million, net of $0.8 million of cash acquired was as follows: December 31, 2020 (in thousands) Trade receivables $ 2,722 Other current assets (excluding cash) 221 Property, plant and equipment 2,382 Goodwill 71,585 Definite-lived intangible assets 24,540 Other long-term assets 2,055 Current liabilities (2,823) Deferred tax liabilities (2,529) Other long-term liabilities (1,123) Total purchase price allocation $ 97,030 The purchase price allocation of $36.9 million, net of $0.5 million of cash acquired was as follows: August 6, 2020 (in thousands) Trade receivables $ 1,500 Inventories 551 Other current assets (excluding cash) 182 Property, plant and equipment 1,648 Goodwill 19,457 Definite-lived intangible assets 16,230 Other long-term assets 849 Current liabilities (1,360) Deferred tax liabilities (1,467) Other long-term liabilities (740) Total purchase price allocation $ 36,850 The purchase price allocation of $376.7 million, net of $3.1 million of cash acquired was as follows: January 3, 2020 (in thousands) Trade receivables $ 6,451 Inventories 8,468 Other current assets (excluding cash) 3,494 Property, plant and equipment 10,033 Goodwill 210,196 Definite-lived intangible assets 183,540 Other long-term assets 5,920 Current liabilities (5,188) Deferred tax liabilities (38,529) Other long-term liabilities (7,664) Total purchase price allocation $ 376,721
Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination	The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 17,340 13 Developed technology 3,685 3 Other intangible assets 1,101 2 Total definite-lived intangible assets $ 22,126 11 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 252,900 14 Other intangible assets 4,900 2 Backlog 8,900 1 Total definite-lived intangible assets $ 266,700 13 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 16,080 9 Developed technology 3,940 5 Other intangible assets 4,520 4 Total definite-lived intangible assets $ 24,540 7 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 14,740 13 Other intangible assets 1,490 3 Total definite-lived intangible assets $ 16,230 12 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 170,390 19 Trade name 7,330 10 Other intangible assets 5,820 3 Total definite-lived intangible assets $ 183,540 18
Schedule of Pro Forma Information	Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) (unaudited) Revenue $ 914,607 $ 706,250 $ 1,767,096 $ 1,434,708 Net income attributable to common shareholders 96,365 74,408 138,712 85,249 June 27, 2020 Three Months Ended Six Months Ended (unaudited) (unaudited) Revenue $ 682,584 $ 1,389,661 Net income attributable to common shareholders 67,383 123,088

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	6 Months Ended
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	Jun. 26, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 66,334 $ 57,357 $ 131,230 $ 117,398 Services and products transferred at a point in time 110,360 59,192 222,374 145,147 Total RMS revenue 176,694 116,549 353,604 262,545 DSA Services and products transferred over time 539,790 442,447 1,040,258 881,011 Services and products transferred at a point in time 304 117 1,014 236 Total DSA revenue 540,094 442,564 1,041,272 881,247 Manufacturing Services and products transferred over time 95,974 41,317 146,542 78,631 Services and products transferred at a point in time 101,845 82,154 197,755 167,220 Total Manufacturing revenue 197,819 123,471 344,297 245,851 Total revenue $ 914,607 $ 682,584 $ 1,739,173 $ 1,389,643 Revenue for each significant product or service offering is as follows: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS $ 176,694 $ 116,549 $ 353,604 $ 262,545 DSA 540,094 442,564 1,041,272 881,247 Manufacturing 197,819 123,471 344,297 245,851 Total revenue $ 914,607 $ 682,584 $ 1,739,173 $ 1,389,643 Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: June 26, 2021 $ 491,619 $ 275,706 $ 90,565 $ 55,133 $ 1,584 $ 914,607 June 27, 2020 382,918 190,935 71,543 35,965 1,223 682,584 Six Months Ended: June 26, 2021 $ 940,101 $ 513,241 $ 167,672 $ 114,579 $ 3,580 $ 1,739,173 June 27, 2020 789,630 381,197 148,176 67,794 2,846 1,389,643
Schedule of Estimated Revenue Related to Performance Obligations	The following table inclu des estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of June 26, 2021: Revenue Expected to be Recognized in Future Periods Less than 1 Year 1 to 3 Years 4 to 5 Years Beyond 5 Years Total (in thousands) DSA $ 287,948 $ 211,364 $ 8,893 $ 359 $ 508,564 Manufacturing 7,561 923 — — 8,484 Total $ 295,509 $ 212,287 $ 8,893 $ 359 $ 517,048
Schedule of Client Receivables, Contract Assets and Contract Liabilities	The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: June 26, 2021 December 26, 2020 (in thousands) Balances from contracts with customers: Client receivables $ 480,533 $ 489,042 Contract assets (unbilled revenue) 171,032 135,400 Contract liabilities (current and long-term deferred revenue) 249,585 227,417 Contract liabilities (customer contract deposits) 44,981 42,244

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
SEGMENT INFORMATION (Tables)	Jun. 26, 2021
Segment Reporting [Abstract]
Schedule of Revenue and Other Financial Information by Business Segment	The following table presents revenue and other financial information by reportable segment: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS Revenue $ 176,694 $ 116,549 $ 353,604 $ 262,545 Operating income 42,580 3,844 87,515 31,217 Depreciation and amortization 9,844 9,126 19,523 17,878 Capital expenditures 8,512 6,621 11,495 12,033 DSA Revenue $ 540,094 $ 442,564 $ 1,041,272 $ 881,247 Operating income 104,514 72,241 195,463 144,524 Depreciation and amortization 43,588 41,101 88,196 82,431 Capital expenditures 20,473 16,175 37,513 30,904 Manufacturing Revenue $ 197,819 $ 123,471 $ 344,297 $ 245,851 Operating income 56,717 42,930 106,154 84,042 Depreciation and amortization 13,952 6,236 20,521 12,602 Capital expenditures 13,602 3,037 20,712 8,198
Reconciliation of Segment Operating Income to Consolidated Operating Income	Reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows: Operating Income Depreciation and Amortization Capital Expenditures June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Three Months Ended: Total reportable segments $ 203,811 $ 119,015 $ 67,384 $ 56,463 $ 42,587 $ 25,833 Unallocated corporate (66,261) (42,247) 722 745 3,844 967 Total consolidated $ 137,550 $ 76,768 $ 68,106 $ 57,208 $ 46,431 $ 26,800 Six Months Ended: Total reportable segments $ 389,132 $ 259,783 $ 128,240 $ 112,911 $ 69,720 $ 51,135 Unallocated corporate (127,879) (88,734) 1,373 1,557 4,741 1,386 Total consolidated $ 261,253 $ 171,049 $ 129,613 $ 114,468 $ 74,461 $ 52,521
Revenue Disaggregated by Products and Services and Geographic Area	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 66,334 $ 57,357 $ 131,230 $ 117,398 Services and products transferred at a point in time 110,360 59,192 222,374 145,147 Total RMS revenue 176,694 116,549 353,604 262,545 DSA Services and products transferred over time 539,790 442,447 1,040,258 881,011 Services and products transferred at a point in time 304 117 1,014 236 Total DSA revenue 540,094 442,564 1,041,272 881,247 Manufacturing Services and products transferred over time 95,974 41,317 146,542 78,631 Services and products transferred at a point in time 101,845 82,154 197,755 167,220 Total Manufacturing revenue 197,819 123,471 344,297 245,851 Total revenue $ 914,607 $ 682,584 $ 1,739,173 $ 1,389,643 Revenue for each significant product or service offering is as follows: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS $ 176,694 $ 116,549 $ 353,604 $ 262,545 DSA 540,094 442,564 1,041,272 881,247 Manufacturing 197,819 123,471 344,297 245,851 Total revenue $ 914,607 $ 682,584 $ 1,739,173 $ 1,389,643 Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: June 26, 2021 $ 491,619 $ 275,706 $ 90,565 $ 55,133 $ 1,584 $ 914,607 June 27, 2020 382,918 190,935 71,543 35,965 1,223 682,584 Six Months Ended: June 26, 2021 $ 940,101 $ 513,241 $ 167,672 $ 114,579 $ 3,580 $ 1,739,173 June 27, 2020 789,630 381,197 148,176 67,794 2,846 1,389,643
Summary of Unallocated Corporate Overhead	A summary of unallocated corporate expense consists of the following: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Stock-based compensation $ 10,417 $ 8,203 $ 18,059 $ 14,907 Compensation, benefits, and other employee-related expenses 25,924 20,749 53,286 42,729 External consulting and other service expenses 6,301 4,917 13,657 7,386 Information technology 4,117 4,235 8,212 7,951 Depreciation 722 745 1,373 1,557 Acquisition and integration 15,036 869 25,596 7,852 Other general unallocated corporate 3,744 2,529 7,696 6,352 Total unallocated corporate expense $ 66,261 $ 42,247 $ 127,879 $ 88,734

SUPPLEMENTAL BALANCE SHEET IN_2

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)	6 Months Ended
SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)	Jun. 26, 2021
Supplemental Balance Sheet Information [Abstract]
Composition of Net Trade Receivables	The composition of trade receivables and contract assets, net is as follows: June 26, 2021 December 26, 2020 (in thousands) Client receivables $ 480,533 $ 489,042 Unbilled revenue 171,032 135,400 Total 651,565 624,442 Less: Allowance for doubtful accounts (7,538) (6,702) Trade receivables and contract assets, net $ 644,027 $ 617,740
Composition of Inventories	The composition of inventories is as follows: June 26, 2021 December 26, 2020 (in thousands) Raw materials and supplies $ 32,071 $ 28,317 Work in process 28,314 36,755 Finished products 133,956 120,623 Inventories $ 194,341 $ 185,695
Composition of Other Current Assets	The composition of other current assets is as follows: June 26, 2021 December 26, 2020 (in thousands) Prepaid income tax $ 117,811 $ 68,462 Short-term investments 1,037 1,024 Restricted cash 3,118 3,074 Other current assets $ 121,966 $ 72,560
Composition of Other Assets	The composition of other assets is as follows: June 26, 2021 December 26, 2020 (in thousands) Venture capital investments $ 174,420 $ 197,100 Strategic equity investments 39,342 24,704 Life insurance policies 48,715 43,827 Other long-term income tax assets 23,153 23,485 Restricted cash 1,403 1,621 Long-term pension assets 34,362 31,915 Other 36,399 29,974 Other assets $ 357,794 $ 352,626
Composition of Other Current Liabilities	The composition of other current liabilities is as follows: June 26, 2021 December 26, 2020 (in thousands) Current portion of operating lease right-of-use liabilities $ 31,741 $ 24,674 Accrued income taxes 39,066 24,884 Customer contract deposits 44,981 42,244 Other 16,511 10,675 Other current liabilities $ 132,299 $ 102,477
Composition of Other Long-Term Liabilities	The composition of other long-term liabilities is as follows: June 26, 2021 December 26, 2020 (in thousands) U.S. Transition Tax $ 43,057 $ 48,781 Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plan 75,221 74,233 Long-term deferred revenue 18,256 19,475 Other 70,843 62,726 Other long-term liabilities $ 207,377 $ 205,215

FAIR VALUE (Tables)

FAIR VALUE (Tables)	6 Months Ended
FAIR VALUE (Tables)	Jun. 26, 2021
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below: June 26, 2021 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 1,592 $ — $ 1,592 Other assets: Life insurance policies — 40,652 — 40,652 Total assets measured at fair value $ — $ 42,244 $ — $ 42,244 Other current liabilities measured at fair value: Contingent consideration $ — $ — $ 23,531 $ 23,531 Other long-term liabilities measured at fair value: Contingent consideration — — 13,776 13,776 Total liabilities measured at fair value $ — $ — $ 37,307 $ 37,307 December 26, 2020 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 2,273 $ — $ 2,273 Other assets: Life insurance policies — 35,770 — 35,770 Total assets measured at fair value $ — $ 38,043 $ — $ 38,043 Other liabilities measured at fair value: Contingent consideration $ — $ — $ 2,328 $ 2,328 Total liabilities measured at fair value $ — $ — $ 2,328 $ 2,328 June 26, 2021 December 26, 2020 Book Value Fair Value Book Value Fair Value 5.5% Senior Notes due 2026 $ — $ — $ 500,000 $ 523,100 4.25% Senior Notes due 2028 500,000 516,850 500,000 523,750 3.75% Senior Notes due 2029 500,000 505,000 — — 4.0% Senior Notes due 2031 500,000 515,000 — —
Rollforward of Contingent Consideration Related to Previous Acquisitions	The following table provides a rollforward of the contingent consideration related to the Company’s business combinations. See Note 2, “Business Combinations.” Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Beginning balance $ 2,328 $ 712 Additions 37,983 2,131 Payments (2,889) (230) Adjustment of previously recorded contingent liability — (468) Foreign currency (115) (3) Ending balance $ 37,307 $ 2,142

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Jun. 26, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 26, 2020 Acquisitions Foreign Exchange June 26, 2021 (in thousands) RMS $ 287,759 $ — $ 97 $ 287,856 DSA 1,378,130 122,227 994 1,501,351 Manufacturing 143,279 603,379 4,202 750,860 Goodwill $ 1,809,168 $ 725,606 $ 5,293 $ 2,540,067
Schedule of Intangible Assets	The following table displays intangible assets, net by major class: June 26, 2021 December 26, 2020 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 9,844 $ (4,291) $ 5,553 $ 29,233 $ (29,233) $ — Technology 138,207 (89,911) 48,296 130,907 (81,305) 49,602 Trademarks and trade names 13,568 (2,704) 10,864 15,870 (5,648) 10,222 Other 33,327 (5,589) 27,738 20,903 (14,633) 6,270 Other intangible assets 194,946 (102,495) 92,451 196,913 (130,819) 66,094 Client relationships 1,431,254 (466,930) 964,324 1,137,331 (415,826) 721,505 Intangible assets $ 1,626,200 $ (569,425) $ 1,056,775 $ 1,334,244 $ (546,645) $ 787,599

LONG-TERM DEBT AND FINANCE LE_2

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS (Tables)	6 Months Ended
LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS (Tables)	Jun. 26, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt and Finance Lease Obligations	Long-term debt, net and finance leases consists of the following: June 26, 2021 December 26, 2020 (in thousands) Term loans $ — $ 146,875 Revolving facility 1,225,383 814,752 5.5% Senior Notes due 2026 — 500,000 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 — 4.0% Senior Notes due 2031 500,000 — Other debt 372 3,457 Finance leases (Note 16) 29,153 29,047 Total debt and finance leases 2,754,908 1,994,131 Less: Current portion of long-term debt 108 47,196 Current portion of finance leases (Note 16) 2,913 3,018 Current portion of long-term debt and finance leases 3,021 50,214 Long-term debt and finance leases 2,751,887 1,943,917 Debt discount and debt issuance costs (24,647) (14,346) Long-term debt, net and finance leases $ 2,727,240 $ 1,929,571
Schedule of Principal Maturities of Existing Debt	Principal maturities of existing debt, giving effect to the amended and restated Credit Agreement, for the periods set forth in the table below, are as follows: Principal (in thousands) 2021 (excluding the six months ended June 26, 2021) $ 108 2022 — 2023 — 2024 264 2025 — Thereafter 2,725,383 Total $ 2,725,755

EQUITY AND NONCONTROLLING INT_2

EQUITY AND NONCONTROLLING INTERESTS (Tables)	6 Months Ended
EQUITY AND NONCONTROLLING INTERESTS (Tables)	Jun. 26, 2021
Equity [Abstract]
Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Numerator: Net income $ 89,916 $ 67,668 $ 153,851 $ 118,505 Less: Net income attributable to noncontrolling interests 1,468 233 3,873 301 Net income attributable to common shareholders $ 88,448 $ 67,435 $ 149,978 $ 118,204 Denominator: Weighted-average shares outstanding - Basic 50,297 49,553 50,138 49,371 Effect of dilutive securities: Stock options, restricted stock units and performance share units 1,037 693 1,087 747 Weighted-average shares outstanding - Diluted 51,334 50,246 51,225 50,118
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 26, 2020 $ (73,884) $ (64,990) $ (138,874) Other comprehensive income before reclassifications 30,296 — 30,296 Amounts reclassified from accumulated other comprehensive income — 1,981 1,981 Net current period other comprehensive income 30,296 1,981 32,277 Income tax expense 933 491 1,424 June 26, 2021 $ (44,521) $ (63,500) $ (108,021)
Rollforward Redeemable Noncontrolling Interest	The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interests: Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Beginning balance $ 25,499 $ 28,647 Adjustment to Vital River redemption value 2,341 — Purchase of a 10% redeemable noncontrolling interest — (3,732) Net income (loss) attributable to noncontrolling interests 2,599 (538) Foreign currency translation 360 (493) Ending balance $ 30,799 $ 23,884

PENSION AND OTHER POST-RETIRE_2

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Tables)	6 Months Ended
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Tables)	Jun. 26, 2021
Retirement Benefits [Abstract]
Schedule of Net Periodic Cost	The following table provides the components of net periodic cost for the Company’s pension, deferred compensation and executive supplemental life insurance retirement plans: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Service cost $ 911 $ 798 $ 1,822 $ 1,595 Interest cost 1,344 2,354 2,688 4,709 Expected return on plan assets (1,983) (2,982) (3,967) (5,963) Amortization of prior service cost (credit) (128) (126) (256) (251) Amortization of net loss 1,110 1,586 2,220 3,172 Other adjustments (572) 125 (572) 250 Net periodic cost $ 682 $ 1,755 $ 1,935 $ 3,512

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
STOCK-BASED COMPENSATION (Tables)	Jun. 26, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	The following table provides stock-based compensation by the financial statement line item in which it is reflected: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Cost of revenue $ 3,012 $ 2,320 $ 5,725 $ 4,355 Selling, general and administrative 14,065 10,823 24,541 19,748 Stock-based compensation, before income taxes 17,077 13,143 30,266 24,103 Provision for income taxes (2,465) (1,988) (4,452) (3,539) Stock-based compensation, net of income taxes $ 14,612 $ 11,155 $ 25,814 $ 20,564

FOREIGN CURRENCY CONTRACTS (Tab

FOREIGN CURRENCY CONTRACTS (Tables)	6 Months Ended
FOREIGN CURRENCY CONTRACTS (Tables)	Jun. 26, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments on Statements of Income	The following table summarizes the effect of the foreign exchange forward contracts entered into to limit the Company’s foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility on the Company’s unaudited condensed consolidated statements of income: June 26, 2021 June 27, 2020 Location of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) (in thousands) Three Months Ended: Interest expense $ (16,190) $ 5,355 $ (19,352) $ — Six Months Ended: Interest expense $ (45,909) $ 19,332 $ (34,419) $ 6,067

RESTRUCTURING AND ASSET IMPAI_2

RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	6 Months Ended
RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	Jun. 26, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Costs	The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income. June 26, 2021 June 27, 2020 Severance and Transition Costs Asset Impairments and Other Costs Total Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Three Months Ended: Cost of services provided and products sold (excluding amortization of intangible assets) $ 393 $ — $ 393 $ 3,299 $ 30 $ 3,329 Selling, general and administrative 1,070 146 1,216 2,089 2,933 5,022 Total $ 1,463 $ 146 $ 1,609 $ 5,388 $ 2,963 $ 8,351 Six Months Ended: Cost of services provided and products sold (excluding amortization of intangible assets) $ 916 $ 40 $ 956 $ 3,545 $ 259 $ 3,804 Selling, general and administrative 1,109 293 1,402 2,172 2,933 5,105 Total $ 2,025 $ 333 $ 2,358 $ 5,717 $ 3,192 $ 8,909 The following table presents restructuring costs by reportable segment for these productivity improvement initiatives: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) RMS $ — $ 769 $ 7 $ 759 DSA 1,074 6,186 1,633 6,498 Manufacturing 535 1,396 869 1,652 Unallocated corporate — — (151) — Total $ 1,609 $ 8,351 $ 2,358 $ 8,909
Rollforward of Company's Severance and Transition Costs and Lease Obligation Liabilities	The following table provides a rollforward for all of the Company’s severance and transition costs and certain lease related costs related to all restructuring activities: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Beginning balance $ 2,221 $ 2,531 $ 5,816 $ 6,405 Expense (excluding non-cash charges) 1,609 6,357 2,358 6,874 Payments / utilization (999) (1,674) (3,465) (5,917) Other non-cash adjustments — — (1,831) — Foreign currency adjustments 11 (15) (36) (163) Ending balance $ 2,842 $ 7,199 $ 2,842 $ 7,199

LEASES (Tables)

LEASES (Tables)	6 Months Ended
LEASES (Tables)	Jun. 26, 2021
Leases [Abstract]
Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements	Right-of-use lease assets and lease liabilities are reported in the Company’s unaudited condensed consolidated balance sheets as follows: June 26, 2021 December 26, 2020 (in thousands) Operating leases Operating lease right-of-use assets, net $ 276,820 $ 178,220 Other current liabilities $ 31,741 $ 24,674 Operating lease right-of-use liabilities 239,484 155,595 Total operating lease liabilities $ 271,225 $ 180,269 Finance leases Property, plant and equipment, net $ 31,684 $ 31,614 Current portion of long-term debt and finance leases $ 2,913 $ 3,018 Long-term debt, net and finance leases 26,240 26,029 Total finance lease liabilities $ 29,153 $ 29,047
Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information	The components of operating and finance lease costs were as follows: Three Months Ended Six Months Ended June 26, 2021 June 27, 2020 June 26, 2021 June 27, 2020 (in thousands) Operating lease costs $ 11,025 $ 7,893 $ 20,376 $ 15,971 Finance lease costs: Amortization of right-of-use assets 840 937 1,688 1,888 Interest on lease liabilities 327 323 655 663 Short-term lease costs 1,332 525 2,282 1,114 Variable lease costs 751 1,067 1,635 2,112 Sublease income (580) (190) (954) (776) Total lease costs $ 13,695 $ 10,555 $ 25,682 $ 20,972 Supplemental cash flow information Six Months Ended June 26, 2021 June 27, 2020 (in thousands) Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 18,578 $ 14,149 Operating cash flows from finance leases 656 663 Finance cash flows from finance leases 1,705 2,467 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 107,306 $ 46,493 Right-of-use lease assets obtained in exchange for new finance lease liabilities 842 735 Lease term and discount rate As of As of June 26, 2021 June 27, 2020 Weighted-average remaining lease term (in years) Operating lease 9.4 8.4 Finance lease 12.1 12.6 Weighted-average discount rate Operating lease 3.7 % 4.2 % Finance lease 4.4 % 4.5 %
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases	As of June 26, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2021 (excluding the six months ended June 26, 2021) $ 20,787 $ 2,131 2022 39,976 3,912 2023 36,660 3,526 2024 35,208 3,294 2025 33,112 3,012 Thereafter 159,581 22,219 Total minimum future lease payments 325,324 38,094 Less: Imputed interest 54,099 8,941 Total lease liabilities $ 271,225 $ 29,153
Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases	As of June 26, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2021 (excluding the six months ended June 26, 2021) $ 20,787 $ 2,131 2022 39,976 3,912 2023 36,660 3,526 2024 35,208 3,294 2025 33,112 3,012 Thereafter 159,581 22,219 Total minimum future lease payments 325,324 38,094 Less: Imputed interest 54,099 8,941 Total lease liabilities $ 271,225 $ 29,153

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	6 Months Ended
BASIS OF PRESENTATION (Details)	Jun. 26, 2021segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	3

BUSINESS COMBINATIONS - Narrati

BUSINESS COMBINATIONS - Narrative (Details) - USD ($) $ in Thousands

Jun. 28, 2021

Mar. 30, 2021

Mar. 29, 2021

Mar. 03, 2021

Dec. 31, 2020

Aug. 06, 2020

Jan. 03, 2020

Jun. 26, 2021

Jun. 27, 2020

Jun. 26, 2021

Jun. 27, 2020

Dec. 26, 2020

Business Acquisition [Line Items]

Goodwill

$ 2,540,067

$ 1,809,168

Vigene Biosciences, Inc.

Business Acquisition [Line Items]

Integration related costs and transaction costs

2,500

Vigene Biosciences, Inc. | Subsequent Event

Business Acquisition [Line Items]

Purchase price

$ 292,500

Consideration contingent upon future performance

$ 57,500

Retrogenix Limited

Business Acquisition [Line Items]

Purchase price

$ 53,100

Consideration contingent upon future performance

6,900

Integration related costs and transaction costs

900

1,700

Cash acquired

8,500

Goodwill

33,625

Definite-lived intangible assets

$ 22,126

Weighted-average amortization life

11 years

Property, plant and equipment

$ 400

Cognate BioServices, Inc.

Business Acquisition [Line Items]

Purchase price

$ 876,100

Integration related costs and transaction costs

11,200

18,400

Cash acquired

70,500

Value of consideration not acquired

$ 15,700

Ownership percentage not acquired

2.00%

Revenue from acquiree included in operating results

34,800

Operating income from acquiree included in operating results

1,100

Goodwill

$ 603,379

Definite-lived intangible assets

$ 266,700

Weighted-average amortization life

13 years

Property, plant and equipment

$ 52,082

Distributed Bio, Inc.

Business Acquisition [Line Items]

Purchase price

$ 97,000

Consideration contingent upon future performance

21,000

Integration related costs and transaction costs

200

900

Cash acquired

800

Cash portion of consideration transferred

80,800

Payments to settle promissory note

3,000

Contingent consideration liability

14,000

Goodwill

71,585

Definite-lived intangible assets

$ 24,540

Weighted-average amortization life

7 years

Property, plant and equipment

$ 2,382

Cellero, LLC

Business Acquisition [Line Items]

Purchase price

$ 36,900

Integration related costs and transaction costs

200

600

Cash acquired

500

Goodwill, amount expected to be deductible for tax purposes

10,800

Goodwill

19,457

Definite-lived intangible assets

$ 16,230

Weighted-average amortization life

12 years

Property, plant and equipment

$ 1,648

HemaCare Corporation

Business Acquisition [Line Items]

Purchase price

$ 376,700

Integration related costs and transaction costs

$ 300

$ 100

400

$ 5,800

Cash acquired

3,100

Goodwill

210,196

Definite-lived intangible assets

$ 183,540

Weighted-average amortization life

18 years

Property, plant and equipment

$ 10,033

Other Acquisitions

Business Acquisition [Line Items]

Purchase price

$ 35,400

Consideration contingent upon future performance

17,500

Cash portion of consideration transferred

19,500

$ 5,500

Contingent consideration liability

$ 15,900

Future performance period

3 years

Goodwill

$ 17,300

Definite-lived intangible assets

15,200

Property, plant and equipment

$ 3,000

Other Acquisitions | Supplier Relationships

Business Acquisition [Line Items]

Weighted-average amortization life

4 years

Depreciation and Amortization Expense | Cognate BioServices, Inc.

Business Acquisition [Line Items]

Adjustments related to prior period

9,500

10,200

Depreciation and Amortization Expense | HemaCare Corporation

Business Acquisition [Line Items]

Adjustments related to prior period

400

Interest Expense | Cognate BioServices, Inc.

Business Acquisition [Line Items]

Adjustments related to prior period

$ 2,200

$ 4,100

BUSINESS COMBINATIONS - Purchas

BUSINESS COMBINATIONS - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Mar. 30, 2021	Mar. 29, 2021	Dec. 31, 2020	Dec. 26, 2020	Aug. 06, 2020	Jan. 03, 2020
Business Acquisition [Line Items]
Goodwill	$ 2,540,067				$ 1,809,168
Retrogenix Limited
Business Acquisition [Line Items]
Trade receivables		$ 2,266
Other current assets (excluding cash)		209
Property, plant and equipment		400
Goodwill		33,625
Definite-lived intangible assets		22,126
Other long-term assets		1,385
Current liabilities		(1,569)
Deferred tax liabilities		(4,174)
Other long-term liabilities		(1,205)
Total purchase price allocation		$ 53,063
Cognate BioServices, Inc.
Business Acquisition [Line Items]
Trade receivables			$ 16,564
Inventories			4,231
Other current assets (excluding cash)			9,840
Property, plant and equipment			52,082
Operating lease right-of-use assets, net			34,349
Goodwill			603,379
Definite-lived intangible assets			266,700
Other long-term assets			6,098
Deferred revenue			(18,582)
Current liabilities			(32,517)
Operating lease right-of-use liabilities			(31,383)
Deferred tax liabilities			(34,256)
Other long-term liabilities			(414)
Total purchase price allocation			$ 876,091
Distributed Bio, Inc.
Business Acquisition [Line Items]
Trade receivables				$ 2,722
Other current assets (excluding cash)				221
Property, plant and equipment				2,382
Goodwill				71,585
Definite-lived intangible assets				24,540
Other long-term assets				2,055
Current liabilities				(2,823)
Deferred tax liabilities				(2,529)
Other long-term liabilities				(1,123)
Total purchase price allocation				$ 97,030
Cellero, LLC
Business Acquisition [Line Items]
Trade receivables						$ 1,500
Inventories						551
Other current assets (excluding cash)						182
Property, plant and equipment						1,648
Goodwill						19,457
Definite-lived intangible assets						16,230
Other long-term assets						849
Current liabilities						(1,360)
Deferred tax liabilities						(1,467)
Other long-term liabilities						(740)
Total purchase price allocation						$ 36,850
HemaCare Corporation
Business Acquisition [Line Items]
Trade receivables							$ 6,451
Inventories							8,468
Other current assets (excluding cash)							3,494
Property, plant and equipment							10,033
Goodwill							210,196
Definite-lived intangible assets							183,540
Other long-term assets							5,920
Current liabilities							(5,188)
Deferred tax liabilities							(38,529)
Other long-term liabilities							(7,664)
Total purchase price allocation							$ 376,721

BUSINESS COMBINATIONS - Definit

BUSINESS COMBINATIONS - Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 30, 2021	Mar. 29, 2021	Dec. 31, 2020	Aug. 06, 2020	Jan. 03, 2020
Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 22,126
Weighted-average amortization life	11 years
Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 266,700
Weighted-average amortization life		13 years
Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 24,540
Weighted-average amortization life			7 years
Cellero, LLC
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 16,230
Weighted-average amortization life				12 years
HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 183,540
Weighted-average amortization life					18 years
Customer and client relationships \| Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 17,340
Weighted-average amortization life	13 years
Customer and client relationships \| Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 252,900
Weighted-average amortization life		14 years
Customer and client relationships \| Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 16,080
Weighted-average amortization life			9 years
Customer and client relationships \| Cellero, LLC
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 14,740
Weighted-average amortization life				13 years
Customer and client relationships \| HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 170,390
Weighted-average amortization life					19 years
Developed technology \| Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 3,685
Weighted-average amortization life	3 years
Developed technology \| Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 3,940
Weighted-average amortization life			5 years
Trade name \| HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 7,330
Weighted-average amortization life					10 years
Other intangible assets \| Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 1,101
Weighted-average amortization life	2 years
Other intangible assets \| Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 4,900
Weighted-average amortization life		2 years
Other intangible assets \| Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 4,520
Weighted-average amortization life			4 years
Other intangible assets \| Cellero, LLC
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 1,490
Weighted-average amortization life				3 years
Other intangible assets \| HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 5,820
Weighted-average amortization life					3 years
Backlog \| Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 8,900
Weighted-average amortization life		1 year

BUSINESS COMBINATIONS - Pro For

BUSINESS COMBINATIONS - Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Cognate BioServices, Inc.
Business Acquisition [Line Items]
Revenue	$ 914,607	$ 706,250	$ 1,767,096	$ 1,434,708
Net income attributable to common shareholders	$ 96,365	74,408	$ 138,712	85,249
HemaCare Corporation
Business Acquisition [Line Items]
Revenue		682,584		1,389,661
Net income attributable to common shareholders		$ 67,383		$ 123,088

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 914,607	$ 682,584	$ 1,739,173	$ 1,389,643
RMS
Disaggregation of Revenue [Line Items]
Total revenue	176,694	116,549	353,604	262,545
RMS \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	66,334	57,357	131,230	117,398
RMS \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	110,360	59,192	222,374	145,147
DSA
Disaggregation of Revenue [Line Items]
Total revenue	540,094	442,564	1,041,272	881,247
DSA \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	539,790	442,447	1,040,258	881,011
DSA \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	304	117	1,014	236
Manufacturing
Disaggregation of Revenue [Line Items]
Total revenue	197,819	123,471	344,297	245,851
Manufacturing \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	95,974	41,317	146,542	78,631
Manufacturing \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	$ 101,845	$ 82,154	$ 197,755	$ 167,220

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Estimated Revenue Related to Performance Obligations (Details) $ in Thousands	Jun. 26, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 517,048
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-06-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 295,509
Performance obligations expected to be satisfied, expected timing	9 months 18 days
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 212,287
Performance obligations expected to be satisfied, expected timing	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 8,893
Performance obligations expected to be satisfied, expected timing	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 359
Performance obligations expected to be satisfied, expected timing	1 year
DSA
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 508,564
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-06-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	287,948
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	211,364
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	8,893
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	359
Manufacturing
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	8,484
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-06-27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	7,561
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	923
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	0
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 0

REVENUE FROM CONTRACTS WITH C_5

REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 26, 2021	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Revenue from Contract with Customer [Abstract]
Payment terms		30 days
Unpaid advanced client billings	$ 19,000	$ 19,000		$ 16,000
Contract liabilities (customer contract deposits)	44,981	$ 44,981		$ 42,244
Percentage of unbilled revenue billed during period		80.00%	75.00%
Amount of unbilled revenue billed during period		$ 135,000	$ 122,000
Percentage of contract liabilities recognized as revenue during period		75.00%	75.00%
Amount of contract liabilities recognized as revenue		$ 227,000	$ 193,000
Lease revenue	$ 6,300	$ 6,300

REVENUE FROM CONTRACTS WITH C_6

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Revenue from Contract with Customer [Abstract]
Client receivables	$ 480,533	$ 489,042
Contract assets (unbilled revenue)	171,032	135,400
Contract liabilities (current and long-term deferred revenue)	249,585	227,417
Contract liabilities (customer contract deposits)	$ 44,981	$ 42,244

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Jun. 26, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	3

SEGMENT INFORMATION - Revenue a

SEGMENT INFORMATION - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Segment Reporting Information [Line Items]
Revenue	$ 914,607	$ 682,584	$ 1,739,173	$ 1,389,643
Operating income	137,550	76,768	261,253	171,049
Depreciation and amortization	68,106	57,208	129,613	114,468
Capital expenditures	46,431	26,800	74,461	52,521
RMS
Segment Reporting Information [Line Items]
Revenue	176,694	116,549	353,604	262,545
Operating income	42,580	3,844	87,515	31,217
Depreciation and amortization	9,844	9,126	19,523	17,878
Capital expenditures	8,512	6,621	11,495	12,033
DSA
Segment Reporting Information [Line Items]
Revenue	540,094	442,564	1,041,272	881,247
Operating income	104,514	72,241	195,463	144,524
Depreciation and amortization	43,588	41,101	88,196	82,431
Capital expenditures	20,473	16,175	37,513	30,904
Manufacturing
Segment Reporting Information [Line Items]
Revenue	197,819	123,471	344,297	245,851
Operating income	56,717	42,930	106,154	84,042
Depreciation and amortization	13,952	6,236	20,521	12,602
Capital expenditures	$ 13,602	$ 3,037	$ 20,712	$ 8,198

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Segment Reporting Information [Line Items]
Operating income	$ 137,550	$ 76,768	$ 261,253	$ 171,049
Depreciation and amortization	68,106	57,208	129,613	114,468
Capital expenditures	46,431	26,800	74,461	52,521
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	203,811	119,015	389,132	259,783
Depreciation and amortization	67,384	56,463	128,240	112,911
Capital expenditures	42,587	25,833	69,720	51,135
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(66,261)	(42,247)	(127,879)	(88,734)
Depreciation and amortization	722	745	1,373	1,557
Capital expenditures	$ 3,844	$ 967	$ 4,741	$ 1,386

SEGMENT INFORMATION - Revenue P

SEGMENT INFORMATION - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Segment Reporting Information [Line Items]
Total revenue	$ 914,607	$ 682,584	$ 1,739,173	$ 1,389,643
RMS
Segment Reporting Information [Line Items]
Total revenue	176,694	116,549	353,604	262,545
DSA
Segment Reporting Information [Line Items]
Total revenue	540,094	442,564	1,041,272	881,247
Manufacturing
Segment Reporting Information [Line Items]
Total revenue	$ 197,819	$ 123,471	$ 344,297	$ 245,851

SEGMENT INFORMATION - Summary o

SEGMENT INFORMATION - Summary of Unallocated Corporate Overhead (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Segment Reporting Information [Line Items]
Stock-based compensation	$ 17,077	$ 13,143	$ 30,266	$ 24,103
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	10,417	8,203	18,059	14,907
Compensation, benefits, and other employee-related expenses	25,924	20,749	53,286	42,729
External consulting and other service expenses	6,301	4,917	13,657	7,386
Information technology	4,117	4,235	8,212	7,951
Depreciation	722	745	1,373	1,557
Acquisition and integration	15,036	869	25,596	7,852
Other general unallocated corporate	3,744	2,529	7,696	6,352
Total unallocated corporate expense	$ 66,261	$ 42,247	$ 127,879	$ 88,734

SEGMENT INFORMATION - Disaggreg

SEGMENT INFORMATION - Disaggregation of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 914,607	$ 682,584	$ 1,739,173	$ 1,389,643
U.S.
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	491,619	382,918	940,101	789,630
Europe
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	275,706	190,935	513,241	381,197
Canada
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	90,565	71,543	167,672	148,176
Asia Pacific
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	55,133	35,965	114,579	67,794
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 1,584	$ 1,223	$ 3,580	$ 2,846

SUPPLEMENTAL BALANCE SHEET IN_3

SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020	Jun. 27, 2020
Composition of trade receivables
Client receivables	$ 480,533	$ 489,042
Unbilled revenue	171,032	135,400
Total	651,565	624,442
Less: Allowance for doubtful accounts	(7,538)	(6,702)
Trade receivables and contract assets, net	644,027	617,740
Composition of inventories
Raw materials and supplies	32,071	28,317
Work in process	28,314	36,755
Finished products	133,956	120,623
Inventories	194,341	185,695
Composition of other current assets
Prepaid income tax	117,811	68,462
Short-term investments	1,037	1,024
Restricted cash	3,118	3,074	$ 465
Other current assets	121,966	72,560
Composition of other assets
Venture capital investments	174,420	197,100
Strategic equity investments	39,342	24,704
Life insurance policies	48,715	43,827
Other long-term income tax assets	23,153	23,485
Restricted cash	1,403	1,621	$ 1,557
Long-term pension assets	34,362	31,915
Other	36,399	29,974
Other assets	357,794	352,626
Composition of other current liabilities
Current portion of operating lease right-of-use liabilities	31,741	24,674
Accrued income taxes	39,066	24,884
Customer contract deposits	44,981	42,244
Other	16,511	10,675
Other current liabilities	132,299	102,477
Composition of other long-term liabilities
U.S. Transition Tax	43,057	48,781
Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plan	75,221	74,233
Long-term deferred revenue	18,256	19,475
Other	70,843	62,726
Other long-term liabilities	$ 207,377	$ 205,215

VENTURE CAPITAL AND STRATEGIC_2

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Dec. 26, 2020
Equity Method Investments and Joint Ventures [Abstract]
Venture capital investments	$ 174,420		$ 174,420		$ 197,100
Committed contribution	149,500		149,500
Amount funded for venture capital investments	105,200		105,200
Distributions received	18,200	$ 2,400	27,500	$ 3,300
Gains (losses) recognized related to venture capital investments	11,000	$ 23,900	(5,300)	$ 11,900
Strategic equity investments	$ 39,342		$ 39,342		$ 24,704

FAIR VALUE - Fair Value of Asse

FAIR VALUE - Fair Value of Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 1,592	$ 2,273
Other assets:
Life insurance policies	40,652	35,770
Total assets measured at fair value	42,244	38,043
Other current liabilities measured at fair value:
Contingent consideration	23,531
Other long-term liabilities measured at fair value:
Contingent consideration	13,776	2,328
Total liabilities measured at fair value	37,307	2,328
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	0
Other long-term liabilities measured at fair value:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	1,592	2,273
Other assets:
Life insurance policies	40,652	35,770
Total assets measured at fair value	42,244	38,043
Other current liabilities measured at fair value:
Contingent consideration	0
Other long-term liabilities measured at fair value:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	23,531
Other long-term liabilities measured at fair value:
Contingent consideration	13,776	2,328
Total liabilities measured at fair value	$ 37,307	$ 2,328

FAIR VALUE - Contingent Conside

FAIR VALUE - Contingent Consideration (Details) - Contingent Consideration - Level 3 - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 2,328	$ 712
Additions	37,983	2,131
Payments	(2,889)	(230)
Adjustment of previously recorded contingent liability	0	(468)
Foreign currency	(115)	(3)
Ending balance	$ 37,307	$ 2,142

FAIR VALUE - Schedule of Fair V

FAIR VALUE - Schedule of Fair Value of Debt (Details) - Senior Notes - USD ($) $ in Thousands	Jun. 26, 2021	Mar. 27, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
5.5% Senior Notes due 2026
Debt Instrument [Line Items]
Stated interest rate	5.50%		5.50%		5.50%
5.5% Senior Notes due 2026 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 0		$ 500,000
5.5% Senior Notes due 2026 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 0		$ 523,100
4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%		4.25%	4.25%
4.25% Senior Notes due 2028 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000		$ 500,000
4.25% Senior Notes due 2028 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 516,850		$ 523,750
3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%	3.75%	3.75%
3.75% Senior Notes due 2029 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500		$ 0
3.75% Senior Notes due 2029 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 505		$ 0
4.0% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4.00%	4.00%	4.00%
4.0% Senior Notes due 2031 \| Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500		$ 0
4.0% Senior Notes due 2031 \| Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 515		$ 0

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Rollforward of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 26, 2021USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 1,809,168
Acquisitions	725,606
Foreign Exchange	5,293
Ending balance	2,540,067
RMS
Goodwill [Roll Forward]
Beginning balance	287,759
Acquisitions	0
Foreign Exchange	97
Ending balance	287,856
DSA
Goodwill [Roll Forward]
Beginning balance	1,378,130
Acquisitions	122,227
Foreign Exchange	994
Ending balance	1,501,351
Manufacturing
Goodwill [Roll Forward]
Beginning balance	143,279
Acquisitions	603,379
Foreign Exchange	4,202
Ending balance	$ 750,860

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Other intangible assets
Gross	$ 1,626,200	$ 1,334,244
Accumulated Amortization	(569,425)	(546,645)
Net	1,056,775	787,599
Backlog
Other intangible assets
Gross	9,844	29,233
Accumulated Amortization	(4,291)	(29,233)
Net	5,553	0
Technology
Other intangible assets
Gross	138,207	130,907
Accumulated Amortization	(89,911)	(81,305)
Net	48,296	49,602
Trademarks and trade names
Other intangible assets
Gross	13,568	15,870
Accumulated Amortization	(2,704)	(5,648)
Net	10,864	10,222
Other
Other intangible assets
Gross	33,327	20,903
Accumulated Amortization	(5,589)	(14,633)
Net	27,738	6,270
Other intangible assets
Other intangible assets
Gross	194,946	196,913
Accumulated Amortization	(102,495)	(130,819)
Net	92,451	66,094
Client relationships
Other intangible assets
Gross	1,431,254	1,137,331
Accumulated Amortization	(466,930)	(415,826)
Net	$ 964,324	$ 721,505

LONG-TERM DEBT AND FINANCE LE_3

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Mar. 27, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,725,755
Finance leases	29,153		$ 29,047
Total debt and finance leases	2,754,908		1,994,131
Current portion of long-term debt	108		47,196
Current portion of finance leases	2,913		3,018
Current portion of long-term debt and finance leases	3,021		50,214
Long-term debt and finance leases	2,751,887		1,943,917
Debt discount and debt issuance costs	(24,647)		(14,346)
Long-term debt, net and finance leases	2,727,240		1,929,571
Term Loans
Debt Instrument [Line Items]
Long-term debt, gross	0		146,875
Revolving Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,225,383		$ 814,752
Senior Notes \| 5.5% Senior Notes due 2026
Debt Instrument [Line Items]
Stated interest rate	5.50%		5.50%		5.50%
Long-term debt, gross	$ 0		$ 500,000
Senior Notes \| 4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%		4.25%	4.25%
Long-term debt, gross	$ 500,000		$ 500,000
Senior Notes \| 3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%	3.75%	3.75%
Long-term debt, gross	$ 500,000		$ 0
Senior Notes \| 4.0% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4.00%	4.00%	4.00%
Long-term debt, gross	$ 500,000		$ 0
Other Debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 372		$ 3,457

LONG-TERM DEBT AND FINANCE LE_4

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Narrative (Details)	1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 30, 2021	Jun. 26, 2021USD ($)	Mar. 27, 2021USD ($)payment	Jun. 27, 2020USD ($)	Jun. 26, 2021USD ($)	Jun. 27, 2020USD ($)	Dec. 26, 2020USD ($)	Dec. 28, 2019USD ($)	Dec. 29, 2018USD ($)
Debt Instrument [Line Items]
Weighted average interest rate		2.74%			2.74%		3.11%
Deferred financing costs expensed					$ 38,166,000	$ 0
Debt extinguishment and financing costs					$ 27,980,000	0
Number of consecutive fiscal quarters					1 year
Foreign Exchange Forward
Debt Instrument [Line Items]
Derivative amount		$ 400,000,000		$ 400,000,000	$ 400,000,000	400,000,000
Term Loans
Debt Instrument [Line Items]
Prepayments of long-term debt			$ 146,900,000
Deferred financing costs expensed			200,000
Credit Facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Prepayments of long-term debt			135,000,000
$750 Million Term Loan \| Credit Facility
Debt Instrument [Line Items]
Credit facility			$ 750,000,000
Number of quarterly installment payments \| payment			19
$2.05 Billion Credit Facility \| Credit Facility
Debt Instrument [Line Items]
Minimum EBITDA less capital expenditures to consolidated cash interest expense ratio		3.50			3.50
$2.05 Billion Credit Facility \| Credit Facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility			$ 2,050,000,000
5.5% Senior Notes due 2026 \| Senior Notes
Debt Instrument [Line Items]
Prepayments of long-term debt			500,000,000
Deferred financing costs expensed			5,000,000
Aggregate principal amount									$ 500,000,000
Stated interest rate		5.50%			5.50%		5.50%		5.50%
Debt extinguishment and financing costs			21,000,000
Payments for accrued interest			13,000,000
4.25% Senior Notes due 2028 \| Senior Notes
Debt Instrument [Line Items]
Maximum consolidated indebtedness to consolidated EBITDA		4.25			4.25
Aggregate principal amount								$ 500,000,000
Stated interest rate		4.25%			4.25%		4.25%	4.25%
3.75% Senior Notes due 2029 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount			$ 500,000,000
Stated interest rate		3.75%	3.75%		3.75%		3.75%
4.0% Senior Notes due 2031 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount			$ 500,000,000
Stated interest rate		4.00%	4.00%		4.00%		4.00%
$3 Billion Credit Facility \| Credit Facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility		$ 3,000,000,000			$ 3,000,000,000
$3 Billion Credit Facility \| Credit Facility \| Revolving Credit Facility \| Federal Funds Rate
Debt Instrument [Line Items]
Variable interest rate	0.50%
$3 Billion Credit Facility \| Credit Facility \| Revolving Credit Facility \| LIBOR
Debt Instrument [Line Items]
Variable interest rate	1.00%
Senior Notes Due 2029 And 2031 \| Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount			$ 1,000,000,000
Debt extinguishment and financing costs			10,000,000
Senior Notes Due 2029 And 2031 \| Senior Notes \| Cognate BioServices, Inc.
Debt Instrument [Line Items]
Debt extinguishment and financing costs			21,000,000
Payments for accrued interest			$ 13,000,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding		16,700,000			16,700,000		$ 16,000,000
Other Nonoperating Income (Expense) \| Foreign Exchange Forward
Debt Instrument [Line Items]
Foreign currency losses recognized					18,300,000	4,200,000
Interest Expense \| Foreign Exchange Forward
Debt Instrument [Line Items]
Recognized gains from derivatives		$ 5,355,000		$ 0	$ 19,332,000	$ 6,067,000

LONG-TERM DEBT AND FINANCE LE_5

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Principal Maturities of Long Term Debt (Details) $ in Thousands	Jun. 26, 2021USD ($)
Debt Disclosure [Abstract]
2021 (excluding the six months ended June 26, 2021)	$ 108
2022	0
2023	0
2024	264
2025	0
Thereafter	2,725,383
Total	$ 2,725,755

EQUITY AND NONCONTROLLING INT_3

EQUITY AND NONCONTROLLING INTERESTS - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Numerator:
Net income	$ 89,916	$ 67,668	$ 153,851	$ 118,505
Less: Net income attributable to noncontrolling interests	1,468	233	3,873	301
Net income attributable to common shareholders	$ 88,448	$ 67,435	$ 149,978	$ 118,204
Denominator:
Weighted-average shares outstanding—Basic (in shares)	50,297	49,553	50,138	49,371
Effect of dilutive securities:
Stock options, restricted stock units and performance share units (in shares)	1,037	693	1,087	747
Weighted-average shares outstanding—Diluted (in shares)	51,334	50,246	51,225	50,118

EQUITY AND NONCONTROLLING INT_4

EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020	Feb. 29, 2020	Dec. 28, 2019	Apr. 29, 2019
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest						92.00%
Noncontrolling interest ownership percentage	8.00%		8.00%
Citoxlab
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest						90.00%
Noncontrolling interest ownership percentage						10.00%	10.00%
Supplier
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity interest						80.00%
Noncontrolling interest ownership percentage						20.00%
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0.2	0.6	0.2	0.6
Restricted Stock and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)			0.7	0.9
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contractually defined redemption value	$ 20.9		$ 20.9
Citoxlab
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contractually defined redemption value					$ 4

EQUITY AND NONCONTROLLING INT_5

EQUITY AND NONCONTROLLING INTERESTS - Treasury Shares (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Equity, Class of Treasury Stock [Line Items]
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)	100,000	100,000
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments	$ 40.3	$ 23.8
Authorized Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Shares repurchased during period (in shares)	0	0
Remaining authorized repurchase amount	$ 129.1

EQUITY AND NONCONTROLLING INT_6

EQUITY AND NONCONTROLLING INTERESTS - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	$ 2,188,184	$ 1,655,627	$ 2,118,169	$ 1,637,828
Other comprehensive income before reclassifications			30,296
Amounts reclassified from accumulated other comprehensive income			1,981
Net current period other comprehensive income			32,277
Income tax expense	2,449	1,862	1,424	(177)
Ending balance	2,323,280	1,756,725	2,323,280	1,756,725
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(73,884)
Other comprehensive income before reclassifications			30,296
Amounts reclassified from accumulated other comprehensive income			0
Net current period other comprehensive income			30,296
Income tax expense			933
Ending balance	(44,521)		(44,521)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(64,990)
Other comprehensive income before reclassifications			0
Amounts reclassified from accumulated other comprehensive income			1,981
Net current period other comprehensive income			1,981
Income tax expense			491
Ending balance	(63,500)		(63,500)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(127,017)	(218,917)	(138,874)	(178,019)
Ending balance	$ (108,021)	$ (212,714)	$ (108,021)	$ (212,714)

EQUITY AND NONCONTROLLING INT_7

EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Dec. 28, 2019	Apr. 29, 2019
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 25,499	$ 28,647
Adjustment to Vital River redemption value	2,341	0
Purchase of a 10% redeemable noncontrolling interest	0	(3,732)
Net income (loss) attributable to noncontrolling interests	2,599	(538)
Foreign currency translation	360	(493)
Ending balance	$ 30,799	$ 23,884
Citoxlab
Increase (Decrease) in Temporary Equity [Roll Forward]
Noncontrolling interest ownership percentage			10.00%	10.00%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	29.50%	19.40%	20.60%	15.00%
Increase in unrecognized tax benefits	$ 1.6
Unrecognized tax benefits	26.9		$ 26.9
Increase in unrecognized tax benefits that would impact effective tax rate	2.1
Unrecognized tax benefits that would impact effective tax rate	24.6		24.6
Accrued interest on unrecognized tax benefits	2		2
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period	$ 1.1		$ 1.1

PENSION AND OTHER POST-RETIRE_3

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Employee benefits
Service cost	$ 911	$ 798	$ 1,822	$ 1,595
Interest cost	1,344	2,354	2,688	4,709
Expected return on plan assets	(1,983)	(2,982)	(3,967)	(5,963)
Amortization of prior service cost (credit)	(128)	(126)	(256)	(251)
Amortization of net loss	1,110	1,586	2,220	3,172
Other adjustments	(572)	125	(572)	250
Net periodic cost	682	1,755	1,935	3,512
Other Postretirement Benefits Plan
Employee benefits
Net periodic cost	$ 0	$ 0	$ 0	$ 0

PENSION AND OTHER POST-RETIRE_4

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Employee benefits
Net periodic cost	$ 682	$ 1,755	$ 1,935	$ 3,512
Other Postretirement Benefits Plan
Employee benefits
Net periodic cost	$ 0	$ 0	$ 0	$ 0

STOCK-BASED COMPENSATION - Stoc

STOCK-BASED COMPENSATION - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 17,077	$ 13,143	$ 30,266	$ 24,103
Provision for income taxes	(2,465)	(1,988)	(4,452)	(3,539)
Stock-based compensation, net of income taxes	14,612	11,155	25,814	20,564
Cost of revenue
Stock-based compensation expense
Stock-based compensation, before income taxes	3,012	2,320	5,725	4,355
Selling, general and administrative
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 14,065	$ 10,823	$ 24,541	$ 19,748

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock-Based Compensation Grants (Details) shares in Millions	6 Months Ended
	Jun. 26, 2021$ / sharesshares
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	0.2
Stock options weighted average grant date fair value (in dollars per share) \| $ / shares	$ 108.52
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1
Weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 337.45
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1
Weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 407.76
Maximum shares to be awarded under plan (in shares)	0.1

FOREIGN CURRENCY CONTRACTS - Sc

FOREIGN CURRENCY CONTRACTS - Schedule of Derivative Instruments on Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense	$ (16,190)	$ (19,352)	$ (45,909)	$ (34,419)
Foreign Exchange Forward \| Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss)	$ 5,355	$ 0	$ 19,332	$ 6,067

RESTRUCTURING AND ASSET IMPAI_3

RESTRUCTURING AND ASSET IMPAIRMENTS - Restructuring Costs by Classification on the Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,609	$ 8,351	$ 2,358	$ 8,909
Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	393	3,329	956	3,804
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,216	5,022	1,402	5,105
Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,463	5,388	2,025	5,717
Severance and Transition Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	393	3,299	916	3,545
Severance and Transition Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,070	2,089	1,109	2,172
Asset Impairments and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	146	2,963	333	3,192
Asset Impairments and Other Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	30	40	259
Asset Impairments and Other Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 146	$ 2,933	$ 293	$ 2,933

RESTRUCTURING AND ASSET IMPAI_4

RESTRUCTURING AND ASSET IMPAIRMENTS - Restructuring Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Segment Reporting Information [Line Items]
Restructuring costs	$ 1,609	$ 8,351	$ 2,358	$ 8,909
Unallocated corporate
Segment Reporting Information [Line Items]
Restructuring costs	0	0	(151)	0
RMS
Segment Reporting Information [Line Items]
Restructuring costs	0	769	7	759
DSA
Segment Reporting Information [Line Items]
Restructuring costs	1,074	6,186	1,633	6,498
Manufacturing
Segment Reporting Information [Line Items]
Restructuring costs	$ 535	$ 1,396	$ 869	$ 1,652

RESTRUCTURING AND ASSET IMPAI_5

RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition Costs Liability (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Restructuring Reserve [Roll Forward]
Beginning balance	$ 2,221	$ 2,531	$ 5,816	$ 6,405
Expense (excluding non-cash charges)	1,609	6,357	2,358	6,874
Payments / utilization	(999)	(1,674)	(3,465)	(5,917)
Other non-cash adjustments	0	0	(1,831)	0
Foreign currency adjustments	11	(15)	(36)	(163)
Ending balance	$ 2,842	$ 7,199	$ 2,842	$ 7,199

RESTRUCTURING AND ASSET IMPAI_6

RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Mar. 27, 2021	Dec. 26, 2020	Jun. 27, 2020	Mar. 28, 2020	Dec. 28, 2019
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	$ 2,842	$ 2,221	$ 5,816	$ 7,199	$ 2,531	$ 6,405
Severance and Transition Costs \| Accrued Compensation and Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	$ 2,800			7,000
Severance and Transition Costs \| Other Long-Term Liabilities
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities				$ 200

LEASES - Right-of-Use Lease Ass

LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Leases [Abstract]
Operating lease right-of-use assets, net	$ 276,820	$ 178,220
Other current liabilities	31,741	24,674
Operating lease right-of-use liabilities	239,484	155,595
Total operating lease liabilities	271,225	180,269
Property, plant and equipment, net	31,684	31,614
Current portion of long-term debt and finance leases	2,913	3,018
Long-term debt, net and finance leases	26,240	26,029
Total finance lease liabilities	$ 29,153	$ 29,047
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current portion of long-term debt and finance leases	Current portion of long-term debt and finance leases
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt, net and finance leases	Long-term debt, net and finance leases

LEASES - Components of Operatin

LEASES - Components of Operating and Finance Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020	Jun. 26, 2021	Jun. 27, 2020
Leases [Abstract]
Operating lease costs	$ 11,025	$ 7,893	$ 20,376	$ 15,971
Amortization of right-of-use assets	840	937	1,688	1,888
Interest on lease liabilities	327	323	655	663
Short-term lease costs	1,332	525	2,282	1,114
Variable lease costs	751	1,067	1,635	2,112
Sublease income	(580)	(190)	(954)	(776)
Total lease costs	$ 13,695	$ 10,555	$ 25,682	$ 20,972

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 26, 2021	Jun. 27, 2020
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 18,578	$ 14,149
Operating cash flows from finance leases	656	663
Finance cash flows from finance leases	1,705	2,467
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	107,306	46,493
Right-of-use lease assets obtained in exchange for new finance lease liabilities	$ 842	$ 735

LEASES - Weighted Average Remai

LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)	Jun. 26, 2021	Jun. 27, 2020
Weighted-average remaining lease term (in years)
Operating lease	9 years 4 months 24 days	8 years 4 months 24 days
Finance lease	12 years 1 month 6 days	12 years 7 months 6 days
Weighted-average discount rate
Operating lease	3.70%	4.20%
Finance lease	4.40%	4.50%

LEASES - Schedule of Future Min

LEASES - Schedule of Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Dec. 26, 2020
Operating Leases
2021 (excluding the six months ended June 26, 2021)	$ 20,787
2022	39,976
2023	36,660
2024	35,208
2025	33,112
Thereafter	159,581
Total minimum future lease payments	325,324
Less: Imputed interest	54,099
Total lease liabilities	271,225	$ 180,269
Finance Leases
2021 (excluding the six months ended June 26, 2021)	2,131
2022	3,912
2023	3,526
2024	3,294
2025	3,012
Thereafter	22,219
Total minimum future lease payments	38,094
Less: Imputed interest	8,941
Total lease liabilities	$ 29,153	$ 29,047

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Millions	Jun. 26, 2021USD ($)
Lessor, Lease, Description [Line Items]
Future minimum lease payments for leases that have not yet commenced	$ 120
Minimum
Lessor, Lease, Description [Line Items]
Terms for leases that have not yet commenced	8 years
Maximum
Lessor, Lease, Description [Line Items]
Terms for leases that have not yet commenced	15 years